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INTRODUCTION 
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I.1. Lipoprotein lipase: general 
Long chain fatty acids are essential to all mammalian tissues, 
both as constituents of complex lipids necessary for the struc-
tural and .functional integrity of cells and as important energy 
source <1,2). Long chain fatty acids are carried in the circu-
lation as free fatty acids (FFA) bound to albumin (3), as tri-
glyceride-fatty acids <TG-FA) within chylomicrons and very low-
density lipoproteins <VLDL), as phospholipids and esterified 
cholesterol. The uptake of FFA by individual tissues is largely 
a function of their concentration in the blood and of the rate 
of the blood flow through the tissue (1,2).TG-FA however, are 
contained in the core of large particles which cannot cross the 
capillary endothelium. Their removal from the blood depends 
therefore on prior hydrolysis at the capillary lining, a reac-
tion catalyzed by the enzyme lipoprotein lipase (LPL) (4,5,6,7). 
The extent to which circulating lipoprotein TG-FA are taken up 
by individual tissues will depend therefore on the LPL activity 
of each tissue relative to the activity in other tissues (6). 
Since the activity of LPL in various tissues can change rapidly 
under different physiological conditions, the enzyme has a dire-
ctive role in the distribution of plasma TG-FA. Thus LPL is 
important in not only determining the rate, but in addition the 
pattern of uptake of TG-FA from the blood.The ability to change 
the supply of TG-FA according to the specific demands of each 
tissue is of particular importance, since there is essentially 
no mechanism for controlling the distribution of circulating FFA 
to individual tissues <1,2,7). LPL is thus not only the key 
enzyme in the removal of TG from the circulation, but in addi-
tion, its activity provides a means to channel long chain fatty 
acids to individual tissues according to the specific metabolic 
needs of the latter. 
I.2. The characteristics of lipoprotein lipase 
Hahn was the first to report clearing of severe alimentary 
lipemia in dogs after transfusion of heparin containing blood 
(8)- Injection of heparin alone could also lead to clearing of 
blood TG in dogs. In addition to these in vivo studies (9), it 
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was soon thereafter established that in vitro mixing of lipi-
demic plasma with plasma separated from the blood of an animal 
that had received heparin, leads to rapid hydrolysis of the 
lipid (10). These studies suggested that a factor, released into 
the circulation after heparin administration, is able to clear 
alimentary lipidemia under in vivo and in vitro conditions. This 
factor initially called "clearing factor" , was named lipopro-
tein lipase by Korn (11) who showed that the enzyme hydrolyzes 
chylomicron TG. It was established that the enzyme was present 
in several tissues, and located close to the capillary wall 
(14,46) and that there is a direct relationship between the 
level of tissue LPL activity and the rate of lipoprotein TG-FA 
uptake (12). The earliest and most extensive studies have been 
carried out with adipose tissue , which takes up and stores most 
of the circulating TG-FA (6,7,12-15). The highest levels of LPL 
activity are found in heart (16-22), lactating mammary gland 
(23-27) and milk (26,28-30). Other tissues in which LPL has been 
described are lung <31-34), skeletal muscle (35-38), aorta 
(39,40), brain <41), corpus luteum (42,43) and placenta <44,45). 
Organs which do not have LPL cannot utilize circulating lipo-
protein TG-FA and use for energy FFA and glucose. 
The enzyme as isolated from different sources, is a glycoprotein 
with a molecular weight of 57 kD (101) and a carbohydrate con-
tent of 3-10%; the only exception seems to be a smaller mole-
cular weight species isolated from the heart (18,99) and from 
post heparin plasma <54). The enzyme hydrolyzes lipoprotein TG 
to FFA and monoglycerides (at pH 7,5-9.0), at the luminal sur-
face of the capillary endothelium (6,7,67,68), where it is bound 
to heparan sulphate. 
The hydrophobic portion of the heparan sulphate proteoglycan is 
anchored in the phospholipid monolayer of the outer leaflet of 
the endothelial cell plasma membrane. The glycosaminoglycan 
chains of the heparan sulphate proteoglycan exist as part of the 
extracellular endothelial glycocalyx and the strong negative 
charge present on these sulphated polymers provides the basis of 
the electrostatic interaction between the surface of the endo-
thelium and the binding site on the LPL protein. In addition to 
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the heparan sulphate glycosaminoglycan, the enzyme also binds 
apolipoprotein C-II, an essential physiological activator of 
the enzyme, which is present in the surface film of VLDL and 
chylomicrons, via a specific binding site. Two other specific 
sites of the enzyme exist: the catalytical active site and a 
lipid-binding site, to which the phospholipids in the surface of 
the lipoprotein particle bind. The lipoprotein may also interact 
with the endothelial glycosaminoglycan via apolipoprotein E 
(69,70). 
LPL activity in vitro has a pH optimum of 8.4 (98) and is highly 
inhibited by 1M. salt and protamine sulphate (21). In vitro LPL 
can be identified (or is characterized) by the dependency upon a 
specific apoprotein C-II for optimal activity. These three char-
acteristics -alkine pH optimum, activation by serum <apopro-
tein C-II>, and inhibition by high concentrations of sodium 
chloride - have been used to differentiate between LPL and other 
lipases in various tissues. 
·r.3. Regulation of lipoprotein lipase activity: general. 
In order to effectively channel circulating TG-FA to various 
organs according to their specific needs, the enzyme has to 
fulfill two demands: 1. its level has to adjust rapidly and 
specifically to the temporary needs of each organ; 2. its loca-
tion in the tissues should maximize the contact between circula-
ting lipoproteins and enzyme. 
Indeed the location of the enzyme at the luminal surface of the 
capillary endothelium (from which it can be rapidly released by 
heparin), was one of the first reported characteristics of LPL 
(15). 
Studies during the last 30 years have shown that LPL activity 
levels change rapidly under a variety of physiological condi-
tions. 
!.4. Nutritional effects on lipoprotein lipase. 
In the fed animal, a large amount of circulating TG-FA is taken 
up by adipose tissue, reesterified and stored within adipocytes. 
After feeding the activity of LPL is, therefore, high in this 
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tissue. During fasting, LPL activity and thus the uptake of 
extracellular liberated FA decreases greatly. Hormone sensitive 
lipase, that hydrolyzes intracellularly stored TG, becomes 
active in the tissue, leading to the release of FFA into the 
blood (47). Another tissue that takes up a major part of the 
circulating TG-FA is skeletal muscle (6,48,49). In that tissue 
fatty acids are used as an important energy source. This is 
especially the case in muscles containing a large proportion of 
slow twitch, red fibers, such as the soleus. Indeed LPL activity 
is much higher in red, than in white skeletal muscle (37 ,38, 
50,51). Whereas LPL activity does not change in white muscle 
during fasting, it increases in red muscle, enabling the red 
muscles to use VLDL-TG during this period. On a wet weight 
basis, LPL activity is much higher in cardiac, than in skeletal 
muscle: also this activity rises markedly after fasting, indica-
ting that the efficiency of utilisation of plasma TG-FA from 
VLDL increases under fasting conditions. In the rat the lung 
maintains a constant level of LPL activity that seems indepen-
dent of the nutritional status <33), In the mouse, an increase 
in the LPL activity in the lung after a 24 hour fast has been 
reported <32). The normal or high activity of LPL in lung, heart 
and red skeletal muscle during fasting, coupled with the low 
activity in adipose tissue, results in an effective channelling 
of circulating VLDL-TG to tissues which have to be supplied with 
long chain fatty acids for their normal metabolic function. 
Since tissues compete for circulating FFA, the tissues which 
maintain or increase their LPL activity have, in addition, the 
advantage of access to circulating TG-FA during fasting. 
The composition of the diet has an effect on LPL activity 
(83,85,86). LPL activity in adipose tissue is lower in rats fed 
on diets high in fat content, in contrast to diets high in car-
bohydrate. LPL activity is also lower in rats fed on sucrose 
rather than on a starch diet. By contrast, this activity in 
heart and skeletal muscle was greater in rats fed on the high 
fat compared with those fed on the high carbohydrate diets. It 
has been suggested (83) that changes in hormonal balance (exag-
gerated glucocorticoid response to high fat diets (87,88)) and 
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sensitivity (insulin insensitivity on high fat diets (87,89)) 
could be responsible for the relative changes in heart and adi-
pose tissue LPL activities. Differences in hormonal status could 
also account for why feeding a diet rich in rapeseed oil in-
creased LPL activity in adipose tissue (90). However, refeeding 
could at the best in part be responsible as the rats used in the 
latter experiments were starved for 1 day, and then refed for 4 
days on a diet in which erucic acid comprised 43% of the fatty 
acids. Feeding with a diet rich in corn oil, rather than beef 
thallow, has also been reported to increase LPL activity in 
adipose tissue (91). 
I.S. Substrate affinity 
The delivery of circulating TG-FA to specific tissues could also 
be affected by differences in affinity between LPL and lipopro-
teins in various tissues. A comparison between the kinetics of 
TG removal by the isolated perfused rat heart and adipose tissue 
has shown that LPL in heart endothelium has a high substrate 
affinity CKm 0.07 mM TG), whereas the enzyme in the endothelium 
of adipose tissue has a low substrate affinity CKm 0.70 mM TG) 
(52,53). These tissue specific lipases differ not only in kine-
tic characteristics, but also structurally (53,54). It has been 
proposed therefore, that the activity of high and low affinity 
LPL, in heart and adipose tissue respectively, may have an im-
portant physiological role in the regulation of local TG clea-
rance (55). 
I.6. Hormonal regulation 
Present evidence indicates that LPL is synthesized within paren-
chymal cells in the endoplasmatic reticulum as an inactive pre-
cursor and its activation take place before it reaches the trans 
golgi cisternae (102,103). It is released from these cells and 
transported to the luminal surface of the capillary endothelium. 
Very little is known about the mechanism of release from the 
cells, its transport through interstitium and basement membrane 
to the endothelial cell and the mechanism by which it reaches 
15 
the luminal surface of the endothelium (and the - possible-
regulation of these processes). 
On the basis of earlier studies it has been proposed that in 
adipose tissue, LPL exists in two forms - an intracellular pre-
cursor form (LPL-b) and an extracellular form <LPL-a), represen-
ting about 5-10% of total tissue enzyme (56). The transformation 
of LPL-b to LPL-a would be independent of protein synthesis, 
occurring just prior to the release from the cell and could 
therefore represent activation of the precursor enzyme (56). 
These investigators suggested that the high activity of LPL in 
adipose tissue of fed rats results from an increase in enzyme 
protein (57). 
Ashby et al. have proposed a scheme for the synthesis and re-
lease of the enzyme from the adipocyte (58,59). The synthesis of 
a proenzyme is regulated by insulin and corticosteroids (59>; 
the next step is also hormone and energy dependent, but requires 
glucose and probably involves the glycosylation of the proenzyme 
(60,61). Inhibition of glycosylation by tunicamycin completely 
inhibits enzyme secretion < 5, 6 2) .. The "complete" active enzyme 
is released from the cell by microtubular transport, a mechanism 
suggested by the inhibition of enzyme secretion by colchicine 
(63,64). 
In the first step, glucocorticoids probably enhance LPL activity 
by regulation of proenzyme synthesis, (20,34,59,65,66), possibly 
at the level of RNA synthesis (59). The second step, conversion 
of proenzyme to "complete" enzyme is essential for enzyme 
secretion and most probably involves glycosylation of the pro-
enzyme protein <5,60-62). Insulin is supposed to act on <pro)-
enzyme synthesis as well as on the activation. 
A possible additional site of regulation of enzyme activity is 
the inactivation of the "complete" enzyme just prior to its 
release from the cell by adrenalin (58,59), which can rapidly 
alter the functional activity at the endothelial surface. It has 
been suggested (58) that such a rapid change induced by adre-
nergic stimuli would act to stop TG-FA uptake more rapidly than 
changing the rate of enzyme synthesis could do. 
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Gonadal hormones and nutritional factors are known to influence 
the distribution of human fat. Estrogen administration markedly 
lowers adipose tissue LPL in the rat (94-96> but not in man 
(97). Ovariectomy increases LPL activity in the rat (94). 
Progesterone and testosterone do not affect the enzyme activity 
in adipose tissue of either male or ovariectomized rats. The 
decrease of rat adipose tissue LPL after estrogen treatment most 
likely is not caused by inadequate food intake since the rats in 
the different experimental groups had a similar weight gain. It 
is not yet known whether the low adipose tissue LPL activity is 
caused directly by the hormone or whether it is mediated through 
the secretion of prolactin. 
The most striking example of hormonal regulation of LPL activity 
occurs just before parturition and during lactation in rats. The 
non-lactating mammary gland is completely devoid of LPL; how-
ever, shortly before parturition, there is a dramatic rise in 
enzyme activity, while concomittently there is an almost com-
plete loss of enzyme activity from the adipose tissue (23). 
Throughout lactation, LPL remains low in all the fat depots, 
while the levels stay high in the mammary gland until weaning. 
Studies in lactating rats, hypophysectomized on the fifth day 
after parturition, have shown that these dramatic changes in 
enzyme activity are regulated by pituitary prolactin (27>, which 
throughout lactation completely depresses LPL activity in 
adipose tissue, while at the same time, maintaining a very high 
enzyme level in the mammary gland. 
The role of glucagon in the regulation of LPL remains uncertain. 
Glucagon levels are increased by fasting, and glucagon hastens 
the decrease in vitro of adipose tissue LPL activity (81>; still 
the in vivo activity of the enzyme in adipose tissue is increas-
ed in fed or fasting rats injected with glucagon (92). Speake et 
al. suggested that the glucagon preparation may have contained 
some insulin. Furthermore, one cannot exclude that high glucagon 
levels lead to hyperinsulinemia. 
Hormones other than insulin, glucagon and catecholamines have 
also been implicated in the control of the enzyme's activity in 
adipose tissue. Of these, the glucocorticoids are of particular 
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interest with respect to regulation on a longer time scale. The 
activity of the enzyme in adipose tissue has been shown to be 
increased after glucocorticoid injection in vivo (71). Male rats 
injected with hydrocortisone-hemisuccinate (8 mg) corticosterone 
(8 mg) or dexamethasone (0.2 mg) intraperitoneally. Adipose 
tisue LPL released by a low dose of heparin and heart LPL were 
raised in activity 2 to 4 hours after the injection, in fed 
animals. In adrenalectomized rats, sacrificed 3-4 days after the 
operation, adipose tissue LPL activity (acetone-ether powder) 
was decreased both in fed and fasted animals. This effect could 
be abolished by dexamethasone, injected 3 hours before sacri-
fice, only in fasted rats. Ashby et al. <59) measured the LPL 
activity of epididymal fat bodies from rats, starved for 24 
hours during incubation, without heparin, at 37oC in vitro. 
Protein-synthesis-dependent increases in the activity of the 
enzyme occur in the presence of insulin (0.2-2.0 mU/ml) and are 
markedly potentiated by addition of dexamethasone <400 nM) to 
the incubation medium. The magnitude of the rise in LPL activity 
was much greater than in the presence of insulin alone, while 
dexamethasone alone only caused a small increase of the acti-
vity. In these experiments, he used several corticosteroids and 
found that all of these were effective in enhancing the response 
to insulin, although the synthetic compounds, dexamethasone and 
triamcinolone acetonide, are the most potent. Adrenalin (10 ~M) 
antagonizes the increase in the activity of the enzyme in the 
tissue. Ashby et al. (59) came to the conclusion that the 
combined effects of changes in plasma insulin and glucocorticoid 
concentrations are responsible for the changes in adipose tissue 
LPL activity that occur with changes in nutritional status in 
vivo. In earlier experiments De Gasquet and Pequignot found that 
the normally observed changes in LPL activity over a 24-hour 
period were correlated with the corticosteroid levels: high 
levels were associated with low LPL activity and vice versa. 
Krotkiewski (72), using male Sprague-Dawly rats treated the rats 
with dexamethasone (0.02 mg i.p.) for 28 days. In spite of high 
insulin levels (from 43 ~U/ml to 77 ~U/ml) the LPL activity in 
the epididymal fat pad decreased to less than 50% from the 
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initial value in these fasted animals. 
Krausz (73), using male albino rats treated with triamcinolone 
(0.1 and 2.5 mg) for five days and Bagdade <74) who used male 
Sprague-Dawly rats treated with dexamethasone (0.025 mg) for two 
weeks, both found a decrease in adipose tissue LPL from fed 
animals. Bagdade used the heparin-elutable method to measure LPL 
activity (75) and Krausz the acetone-ether powder method (76). 
Cigolini and Smith (82) studied the influence of pharmacological 
<3 ~M) concentrations of hydrocortisone on biopsies of human 
adipose tissue, maintained in culture for one week. Hydrocorti-
sone decreased the acetone-ether LPL activity at high physiolo-
gical (0.3 ~M) and pharmacological <3 ~M) concentrations. The 
presence of insulin <1000 ~U/ml) alone tended to increase the 
LPL activity, although the difference did not reach statistical 
significance. The combination of insulin and glucocorticoids 
caused an increase in LPL activity. The enhancing effect seems 
to be influenced by of the hydrocortisone/insulin ratio. Increa-
sing the glucocorticoid concentration tenfold, while maintainig 
the insulin concentration constant, let to a lower effect on the 
LPL activity. However, increasing the insulin concentrations at 
a given cortisol concentration caused a further increase of LPL 
activity. In the same study the authors found that pharmacol-
ogical hydrocortisone concentrations induce a fall of the number 
of insulin receptors on adipocytes. Recently Speake et al. (92) 
reported that the incorporation of 3H-leucine into LPL during 
incubations of rat epididymal fat bodies in vitro is signifi-
cantly stimulated by dexamethasone (400 nM), whereas total pro-
tein synthesis was unaffected. The stimulation by dexamethasone 
required the presence of insulin (2000 ~U/ml). Taskinen et al. 
(100) studied the lipoprotein patterns and lipolytic activities 
in patients with Cushing's syndrome. They could not find any 
difference between controls and patients in LPL activity in 
biopsies of peripheral adipose tissue and in plasma after an 
intravenous injection of heparin. In contrast to the adipocytes 
of the rat (78), these cells do not have corticotropin receptors 
in humans (79). 
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In adrenalectomized rats (71), a situation with high levels of 
corticotropin, as well as in hypercorticistic rats by treatment 
with glucocorticoids <20,72-74), a situation with suppressed 
corticotropin secretion, LPL activity is decreased in adipose 
tissue. From older, in vitro studies, it is known that cortico-
tropin, just as glucagon and catecholamines, counteract the 
stimulatory effect of insulin on adipose tissue LPL (80,81). In 
in vivo experiments, by Lawson et al. (83), using male rats, fed 
on starch and corn-oil diets for three weeks, a corticotropin 
injection (0.2 U) induced a rapid fall. A fall of 30-35% one 
hour after the injection and lasting for at least six hours of 
adipose tissue LPL activity in winter, but not in the period 
between march and september. 
Chernick et al. (84) did not observe any effect of ACTH on LPL 
activity in the cultured 3T3-Ll cell, although it did stimulate 
intracellular lipolysis. Effects of lipolytic agents on the 
activity of LPL were variable in these cells and concentration 
dependent. LPL activity was decreased only by concentrations of 
adrenalin greater than those inducing maximal intracellular 
lipolysis and the decrease in activity occurred about 30 minutes 
after the increase in glycerol release. 
I.7. Aims of the study. 
Current data strongly suggest the most important role for insu-
lin in the hormonal regulation of adipose tissue LPL activity. 
It is not clear from the literature what the role is of gluco-
corticoids in the regulation of the enzyme. Stress hormones as 
ACTH and adrenalin for example seem to decrease LPL activity or 
to have no effect at all on the enzyme. One of the reasons for 
difficulties in interpreting the data obtained so far is the 
fact that different methods were used to measure LPL activity. 
Another point is, that biological enzyme activities are measured 
in vitro, so that one is not informed on what really happens in 
vivo. 
We have focussed our attention to the influence of physiologi-
cally circulating glucocorticoids, ACTH and insulin on LPL acti-
vity in rats. Aims of the study were: - which role have steroid 
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and peptide hormones in the regulation of adipose tissue LPL? 
- to what degree reflects the adipose tissue LPL activity mea-
sured in vitro that prevailing in situ? - what is the balance 
of in- and efflux of fatty acids in/from adipose tissue under 
various conditions? - What is the influence of a- and ~-adre­
nergic antagonists on adipose tissue LPL and plasma lipopro-
teins? In chapter VIII the effects of antagonists of catechol-
amines on lipoproteins and lipolytic enzymes in post-heparin 
plasma of humans is shown and discussed. To study the effects of 
changes in LPL activity in situ on triglyceride metabolism in 
rats <in different states) the epididymal fat pad was selecti~ 
vely perfused with labeled chylomicrons and VLDL. 
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CHAPTER II 
LIPOPROTEIN LIPASE ACTIVITY AND TRIGLYCERIDE METABOLISM IN 
THE PERFUSED FAT PAD. 
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SUMMARY. 
The in vitro perfused epididymal fat pad of the rat was used to 
study several aspects of the relationship between lipoprotein 
lipase <LPL) activity, hydrolysis rate of lipoprotein triglyce-
rides (TG) and the uptake of liberated fatty acids <FA) by the 
tissue. 
1. In fasted animals 2.0 ± 0.8% and in fed rats 14.4 ± 1.5% of 
the perfused chylomicron-TG was hydrolyzed. For VLDL-TG these 
figures were 3.6 ± 1.6% and 4.8 ± 1.2% respectively. Of the 
perfused chylomicron-TG 1.0 ± 0.2% in fasted and 2.7 ± 0.3% in 
fed animals was taken up in the tissue. For VLDL-TG these fig-
ures were 1.2 ± 0.2% and 0.8 ± 0.2% respectively. 
The hydrolysis rate of chylomicron-TG and the uptake of liberat-
ed fatty acids was positively correlated in fasted (r = 0.60, p 
< 0.05) and fed <r = 0.53, p < 0.05) animals. Therefore chylo-
micron-TG seems to be a better substrate for adipose tissue LPL 
than VLDL-TG in fed animals. 
2. Heparin-releasable LPL activity and chylomicron-TG hydrol-
ysis were strongly correlated in fasted (r = 0.96; p < 0.0005) 
and fed <r = 0.94; p < 0.002) animals: no statistically sig-
nificant correlation was found between heparin-releasable LPL 
activity and uptake of FA (r = 0.71 respectively r = 0.54). 
During all the perfusions a spontaneous LPL-release occurred 
<about 1 o/oo of the tissue activity per min). The sum of the 
in 60 min. released LPL activity and the remaining LPL activity 
in the tissue, was equal to the LPL activity in the non-perfused 
fat pad. 
3. If FA-free albumin was present in the perfusion medium, no 
hydrolysis of chylomicron-TG or uptake of FA occurred. 
4. When the perfusion flow rate was increased from 25 ~1/min to 
100 ~1/min the percentage of the perfused chylomicron-TG hydrol-
yzed, decreased from 40% to 12%, so that the absolute amount of 
FA liberated, remained the same. 
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INTRODUCTION. 
The most important function of adipose tissue is to store and 
liberate fatty acids CFA) (10,13,16,26). The FA are derived from 
de novo synthesis in the adipocyte and from triglyceride CTG)-
rich lipoproteins. Lipoproteine lipase CLPL;EC 3.1.1.34) is the 
enzyme responsible for the hydrolysis of plasma lipoprotein-TG 
and can in this way control the removal of TG-FA from the cir-
culation (17,22,23). The substrates for this enzyme are chyle-
microns and VLDL. After feeding, when chylomicrons appear in the 
blood, adipose tissue LPL rises, while skeletal muscle LPL does 
not; under fasting conditions, when VLDL is the most important 
TG bearing lipoprotein, LPL activity is low in adipose tissue 
and high in skeletal muscle, for which tissue FA is an important 
energy source. Therefore, chylomicron-TG probably represents the 
physiological substrate for adipose tissue LPL. 
It has been demonstrated that LPL is an important enzyme for 
the hydrolysis of plasma triglycerides. LPL deficiency leads to 
gross accumulation of chylomicrons in the plasma, while upon 
specific inhibition of the enzyme activity with antibody either 
in intact laboratory animals or in the in vitro perfused rat 
heart hydrolysis of extracellular triglycerides becomes comple-
tely impaired (6,12,24). Less clear is the direct relationship 
between LPL-activity and the rate at which perfused triglyce-
rides are hydrolyzed. Chen et al. (9) have suggested that be-
sides the enzymatic activity of LPL, additional factors may help 
to regulate the lipoprotein-TG hydrolysis rate. It is also not 
clear whether a relationship exists between the rate of hydrol-
ysis of lipoprotein-TG in the vascular compartment and uptake of 
I 
the hydrolysis products in the tissues. Therefore we set out to 
study this relationship and factors that might influence it. To 
this purpose we used an in situ epididymal fat pad perfusion 
model described by Ho and Meng in 1964 (15). In this model phy-
siological conditions are difficult to maintain, and swelling of 
the tissue may easily occur. Therefore we first established the 
conditions under which the viability of the tissue was main-
tained. 
MATERIALS & METHODS 
Animals. 
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Male rats of the Wistar strain with a weight between 180 to 220 
gram were used. The rats had free access to standard lab chow 
and tap water unless noted otherwise. Lights were on from 09.30 
to 21.30. The fasted groups were deprived of all caloric intake 
16 h before use. 
Perfusion model. 
The perfusion was carried out in principle as described by Ho 
and Meng (15). The left epididymal fat pad was removed, and used 
as the non-perfused control for LPL activity. The testicular 
branch of the right spermatic artery was ligated. The fat pad 
was placed in a gaze wetted with saline (NaCl 0.9% w/v). Tempe-
rature was kept at 37°C. After cannulation of the aorta just 
below the right spermatic artery (and after ligation of lumbar 
arteries and the aorta proximally), perfusion was started with a 
buffered medium (see below) at a flow rate of 100 ~1/min. The 
time between ligation of the aorta and the start of the per-
fusion was less than one minute. The inferior caval vein was 
cannulated just below the inflow of the spermatic vein. Large 
veins entering the vein in this segment were ligated as well as 
the inferior caval vein proximally. 
The fat pad was one way perfused in situ without recirculation. 
The perfusion medium consisted of minimal essential medium CMEM; 
Gibco, Paisley, Scotland) supplemented with L-glutamine, non-
essential amino acids CGibco, Paisley, Scotland), NaHC03 (final 
concentration 26 roM), albumin (Sigma fraction V, St. Louis, USA; 
5% w/v), glucose (5 roM) and insulin CActrapidR 40 U/ml, Novo, 
Denmark; final concentration 100 ~U/ml). When indicated, fatty 
acid-free albumin (Fluka AG, Buchs, Switserland) was used. 
Washed red blood cells were added as oxygen carrier Chaematocrit 
of the medium: 0.20). When indicated, heparin 50 IU/ml CTrombo-
liquine, Organon, Oss, the Netherlands) was added to the perfu-
sion medium. The medium was equilibrated with 95% 02 - 5% C02 by 
gentle continuous bubbling. The vial with medium (6 ml at start) 
was placed in a small dewar vessel which was circulated with 
water of 40°C. The temperature of the medium, entering the aorta 
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was 37·c. The flow rate was governed at the inflow site by a 
peristaltic pump at 100~1/min, unless noted otherwise. After 
perfusion for 150 minutes, the ATP content (60 ± 24 nmoles/g) 
and energy charge (0.91 ± 0.01) of the perfused adipose tissue. 
were similar to that in the non-perfused pad <60 ± 19 nmoles/g 
resp. 0.93 ± 0.01). The pH of the perfusate remained in the 
physiological range (7.35- 7.45). Lactate nor nucleosides were 
detectable in the perfusate. With tritium labeled leucine, added 
to the perfusion medium, we found incorporation of aminoacids in 
the protein fraction of the fat pad, which demonstrated that de 
novo protein synthesis occurred under the above described 
circumstances. If the perfusions were carried out with flow 
rates higher than 200 ~1/min, the fat pads became edematous and 
the ATP level and energy charge dropped to 50% of the control 
values. Fractions of the perfusate <mostly 10 min.-fractions> 
were collected in ice-cooled tubes. After perfusion with TG-rich 
substrates, the perfusion was continued for ten minutes with 
0.9% NaCl (w/v) to remove all the intravascular lipid. 
In experiments u~ing 131I-labeled albumin in the medium it was 
found that no label remained in the tissue after ending the 
perfusion. Therefore no (labeled) chylomicrons remained in the 
vascular compartment after the wash-out with 0.9% NaCl. 
Preparation of TG-rich particles. 
Chylomicrons were obtained in principle following the procedure 
of Belman et al.(S). Through a tube leading into the jejunum a 
solution conta.ining 0. 6% NaCl, 0. 03% KCl and 0. OS% Nembutal 
(Abbott S.A.,Saint Demy sur Avre, France) was infused at a rate 
of 1 to 2 ml per hour. After 1 - 2 hours this solution was 
replaced by a mixture of 0.5 ml Intralipid 20% (Kabi Vitrum, 
Stockholm, Sweden) and 1.5 ml containing 15 ~Ci 1-14c palmitic 
acid (Radioactive materials, Amersham, U.K.) complexed to 20% 
albumin (3). After the fat emulsion was given, infusion was 
continued with the NaCl, KCl and Nembutal solution. When the 
lymph became milky in appearance it was collected for 3 hours. 
From the radioactive label 40% was recovered in this period, 87 
to 93% of which was found in the TG fraction. The TG concen-
tration in the lymph was between 25 and 30 mM. The lymph was 
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centrifuged at 500 g during ten minutes to remove clots. The 
lymph was added to the perfusion medium at a final TG concen-
tration of 1 rnM unless stated otherwise. 
With chylomicrons prepared from donor rats on a normal rat chow 
diet instead of intralipid, similar results were obtained. This 
indicates that neither the fatty acid composition of the 
chylomicron-TG nor the way of preparation largely affects the 
results. 
Overnight fasted rats were used as donor for VLDL. One ml of a 
solution containing 1-14c-palmitic acid (10 J.l.Ci) 1 complexed to 
albumin 20% was injected into the tail vein. After thirty 
minutes the animals were anaesthesized with ether. Blood was 
collected from the aorta in tubes containing Na2 EDTA (final 
concentration 5 roM) and centrifugated for 15 min at 2000 g 
Plasma from three rats was pooled. The plasma (9 ml) was trans-
ferred into an ultracentrifuge tube (Beckman, polyallomere ul-
tracentrifugation tube) and overlayered with 2 ml NaCl 0.9% 
(w/v). The VLDL-fraction was isolated by centrifugation' at 
200.000 g in a swinging bucket rotor (Beckman SW 41) for 20 
hours. The top fraction containing VLDL was collected by tube-
slicing. Recovery of radioactivity in the VLDL-fraction was 1 -
2% of the injected dose; chemically measured TG concentration 
in the VLDL containing top fraction was 3 - 4 mM. VLDL fraction 
was added to the perfusion medium at a final TG concentration of 
1 roM. 
By determining the FA composition of chylomicron-TG and medium, 
before and after perfusion, using gas chromatography, we observ-
ed that adipose tissue LPL has a low substrate specificity and 
is unable to discriminate between long chain saturated and un-
saturated fatty acids. This is in accordance with the in vitro 
data of Marly et al. using milk-lipoprotein lipase (19) and with 
those of Abumrad et al. (1), who found that oleate, stearate, 
linoleate and palmitate are all good substrates for uptake by 
adipocytes. 
Analytical methods. 
Lipid analysis. 100 J.l.l of the perfusion medium and of each 
perfusate fraction was extracted according to Bligh and Dyer 
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(4). For the calculation of the recovery of fatty acids and 
triglycerides an internal standard was added prior to the 
extraction procedure (5000 dpm 3H-palmitic acid and 5000 dpm 
tripalmitylglycerol labeled with 3H in the palmitic acid moiety. 
The organic phase was collected and evaporated under a nitrogen 
stream. Lipids were dissolved in 100 ~1 chloroform and quan-
titatively transferred to a thin layer silicagel plate (0.25 
mm; Merck, Darmstadt, BRD). The internal standard samples were 
brought on the silicagel, to determine the place of fatty acids 
and triglycerides after development. The plates were developed 
with a heptane-ether-acetic acid (60:40:1, v:v:v) mixture. The 
place of internal standards was determined and the areas of the 
different lipid fractions <fatty acids FA; monoglycerides = 
MG; diglycerides = DG; triglycerides TG) were separately 
scraped off and radioactivity in 3H and 14c was determined by 
liquid scintillation counting. The hydrolysis of triglycerides 
during the perfusion experiments was expressed as the quotient 
of the increment in radioactive free fatty acids divided by the 
radioactivity in the TG-fraction at the start of the perfusion. 
Radioactivity was for 87 to 93% present in TG. The increase in 
radioactivity in the MG and DG fractions after perfusion was 
always negligibly. After the perfusion procedure the fat pad 
was weighed. Part of it was used for lipid extraction (4). 
For the estimation of the recovery, 3H-palmitic acid and 3H-
triglyceride were added before extraction. The chloroform phase 
was evaporated under a nitrogen stream and radioactivity counted 
by liquid scintillation. The uptake of fatty acids in the per-
fused fat pad was expressed as the quotient of radioactivity 
that remained in the fat pad after the perfusion and the total 
radioactivity, in the perfusion-medium at the start, which had 
passed the fat pad during the perfusion-period. 
Lipoprotein lipase measurement. 
The fat pads (perfused and the non-perfused controls) were 
defatted with acetone and diethyl-ether as described by 
Garfinkel et al. <14). Acetone ether powder LPL was extracted in 
Tris-ethylene glycol buffer (50 mmoles Tris in 1 M ethylene 
glycol, pH:8.0 ; 2 - 5 mg powder/ml buffer). From the extract 
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and the fractions of the perfusate 100 ~1 was taken to measure 
LPL. The substrate of the LPL-assay consisted of a glycerol 
stabilized glycerol-tri 9,10 (n)-3H-oleate phospholipid emulsion 
as described in detail by Nilsson-Ehle et al. (20). The activity 
is expressed as milli units <= nmoles free fatty acid released 
per minute). Serum of overnight fasted male rats served as LPL 
activator. To study if the above described medium served as a 
good LPL stabilizer, in vitro experiments were carried out, 
using the above described perfusion medium and Krebs-Ringer 
solution (pH:8.3, supplemented with albumin, 5% w/v and glucose, 
5 roM). As LPL source, we used the heparin-elutable LPL activity 
from adipose tissue after an incubation for 40 minutes at 37•c 
as described by Taskinen et al.(25). The LPL activity measured 
in this medium was said to be 100%. One ml of this medium was 
then added to 10 ml of the above described perfusion and Krebs 
Ringer medium, and held at 37•c for another twenty minutes. The 
LPL activity fell in this period from 100% to 92% using the 
perfusion medium and to 78% of the LPL activity at the start 
using Krebs-Ringer solution. Therefore, the medium we used in 
our perfusion experiments stabilized LPL activity much better 
than the Krebs-Ringer solution did. 
Other methods. 
Triglycerides (Merck-diagnostica, Darmstadt, BRD> and lactate 
(Boehringer Mannheim, BRD) were determined with an enzymatic 
method, free fatty acids according to Laurell (18> and nucleo-
sides by High Performance Liquid Chromatography. The statistical 
significance of differences between groups was calculated, using 
the unpaired Student's t-test. 
RESULTS. 
Effect of different conditions on lipoprotein lipase activity. 
LPL activity was measured in the perfusate and in the acetone 
ether powder of the epididymal fat pads. Without heparin addi-
tion to the medium a spontaneous release of LPL was detected 
during the whole perfusion period (Fig.l). The activity was 
5-times higher in the fed compared to the fasted animals. Addi-
tion of heparin 60 minutes after the the initiation of the 
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Fig.1 
LPL activity in perfusion medium(= perfusate) affera 70 minutes lastrng perfusion in-fed-and mstea animals (each 
·group consisted of 7 animals). During the last 1 o minutes of the perfusion, heparin (50 llJ/ml) was added. Ttie 
LPL activities are expressed as percentage of the tissue LPL activity'oftnei non-perfused ,lefrbads1(mean.±,SEMY; 
the mean of the latter was taken as 100%. 
perfusion increased the release of enzyme activity especially in 
the pads of fed rats. The percentage of the heparin-releasable 
pool of the LPL activity of the non-perfused fat pad, was in 
both conditions the same. After the perfusion of fat pads of fed 
animals with heparin, the LPL activity remaining in the perfused 
right pad was 83 ± 6% (n = 7) of that in the non perfused left 
pad (100 ± 9%). In fasted animals this decrease by heparin was 
in absolute numbers less clear but percentually the same 
( 8 9 ± 5% vs . 10 0 ± 10% n = 7 ) , when the LPL activity in the 
non-perfused pad is taken as 100% <Fig.l). The difference in 
LPL activity between the perfused and non-perfused fat pad is 
accounted for by the LPL activity in the heparin-releasable 
fraction (11 ± 1% in fasted and 17 ± 2% in fed animals). 
42 
Hydrolysis 
nMoles FA 
5400 
4800 
4200 
3600 
3000 ••• 
2400 
• 
1800 • 
• 1200 • 
• r = 0. 92 
p "0.0001 
600 
1' 2 3 4 mM TG 
Fig.2 
Influence of various chylomicron-TG concentrations (mM) in the perfusion medium on the 
hydrolysis rate (expressed as nmoles FA) using the epididymal fat pad of fed animals. 
Hydrolysis and uptake of TG-rich lipoproteins in the perfused 
fat pad. 
During a sixty minutes lasting perfusion of the right epididymal 
fat pad of fed animals with chylomicrons, a positive correlation 
was found between TG concentration and hydrolysis rate (r = 0.92 
p < 0.0001) using TG concentrations up to 4 mM (Fig.2). The 
uptake of liberated FA was positively correlated (r = 0.85; 
p < 0. 0003) with the TG concentration in the perfusion medium 
(Fig.3). 
Hydrolysis rate and uptake of liberated FA were in these expe-
riments correlated (r = 0.86; p < 0.0002). 
The uptake of FA during different time intervals of the per-
fusion period was measured in four experiments each. 
Uptake 
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Influence of variouschylomicron-TG concentrations(mM) in the perfusion medium on uptake 
of liberated fatty acids (nmoles/pad) by the perfused adipose tissue of fed animals. 
Perfusion of pads from fasted animals were carried out starting 
with a medium containing labeled chylomicrons during twenty 
minutes or after preperfusion of the fat pad for fourty-five 
minutes with unlabeled chylomicrons followed by perfusion with 
labeled chylomicrons. The uptake of 14c-FA was 1.6 ± 0.3% and 
1.4 ± 0.2% respectively. So, preferential uptake of label was 
not found, and triglyceride removal by the perfused adipose 
tissue remained essentially constant during the perfusion 
period. 
The effect of different FA concentrations in the perfusion 
medium, leading to different FA/albumin ratios on TG-hydrolysis 
of chylomicrons were studied (Table I). An increase in the 
concentration of FFA in the perfusion medium (3H-labeled 
palmitic acid complexed to albumin), had no effect on TG-hydrol-
ysis or on the uptake of 14c-FA, liberated from TG. 
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Table I 
The effect of the fatty acid concentration on chylomicron-triglyceride 
hydrolysis and uptake of fatty acids in the perfused fat pado. 
ratio FA/albumin hydrolysis uptake 14-FA* uptake 3H-FA+ 
mol/mol o/o nmol/pad nmol/pad 
1 : 1 
2: 1 
4:1 
19±3 515± 98 404± 62 
12±2 830±293 896±289 
17±3 844± 176 1745±324** 
Results are expressed as mean ± SEM of three separate experiments. In every 
experiment 3H-Iabeled palmitic acid complexed to albumin as well as chylomicrons 
were added to the perfusion medium. 
Uptake of hydrolyzed 14C-Iabeled fatty acids from chylomicrons. 
+· Uptake of 3H-Iabeled palmitic acid complexed to albumin in nmoles per pad. 
Significantly different from the group with ratio FNalbumin 1 : 1 (p < 0.02). 
In the absence of FA <FA-free albumin) hydrolysis of TG could 
not be detected. The uptake in the fat pad of 3H-palmitic acid 1 
complexed with albumin 1 was related to the concentration and 
thus to the ratio of FFA/albumin in the perfusion medium (Table 
I). This indicates that uptake of free fatty acids (bound to 
albumin) is concentration dependent 1 and independent from the 
uptake of fatty acids 1 released into the vascular compartment 
during hydrolysis of chylomicron-TG. 
If the flow rate was changed from 100 ~1 to 25 ~1/min the per-
centage of the perfused chylomicron-TG that was hydrolyzed 
increased with a factor four. However 1 the uptake of liberated 
fatty acids in the tissue did not change (Table II). 
The rate of TG-hydrolysis in chylomicrons was low in fat pads of 
fasted animals and significantly higher when fed animals were 
used. Hydrolysis of VLDL-TG in fasted animals showed a greater 
variation but was not significantly different from that found 
with chylomicrons (Table III). In fed animals the hydrolysis of 
chylomicron-TG was much higher than that of VLDL-TG. 
From the fatty acids liberated from chylomicron-TG during per-
fusion of pads of fasted animals about 50% was taken up in the 
tissue corresponding with 1.0 ± 0.2% of the total amount of 
chylomicron-TG that passed the pads during the perfusion period 
(Table III). The uptake of chylomicron-FA by the perfused adi-
pose tissue after feeding was 2 - 3 times higher than in 
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Table II 
Effect of flow rate on the hydrolysis of chylomicron triglyceride and 
uptake of fatty acids in the perfused fat pad* 
flow rate hydrolysis uptake 14C-FAo uptake 3H-FA+ 
% nmoles/pad nmoles/pad 
25 ul/min 40±6** 669 ± 142 453± 64 
50 ul/min 18± 1 1060 ±333 494± 103 
100 ul/min 12±2 830±293 896±289 
Results are given as mean± SEM ofthree experiments, molar ratio FNalbumin was2:1 
In every experiment 3H-Iabeled palmitic acid complexed to albumin as well as chyle-
microns were added to the perfusion medium. 
Uptake of 14C-Iabeled fatty acids liberated from chylomicrons, TG concentration 1 mM, 
expressed as nmoles per pad 
+ Uptake of 3H-Iabeled palmitic acid complexed to albumin expressed as nmoles per pad 
Significantly different from both other groups (p < 0.05) 
overnight fasted animals. In the fed condition 20% of the fatty 
acids liberated during chylomicron-TG hydrolysis is taken up by 
the adipose tissue. 
In fasted and fed animals a strong correlation between heparin-
releasable LPL activity and TG-hydrolysis of chylomicrons was 
found <r = 0.96, p < 0.0005 respectively r = 0.94, p < 0.0002, 
Table IV) and a much lower correlation existed between acetone 
ether powder LPL activity and chylomicron-TG hydrolysis 
(r = 0.46 respectively r = 0.49). In both conditions a low, and 
statistically not significant relationship was found between 
heparin-releasable LPL-activity and acetone-ether LPL activity 
(r = 0.34 in tasted respectively r = 0.20 in fed animals). In 
these experiments, hydrolysis rate of chylomicron-TG and uptake 
of the liberated fatty acids were significantly correlated with 
each other (r = 0.60 in fasted and r = 0.54 in fed animals, 
p < 0.05). 
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Table Ill 
Hydrolysis of chylomicron-TG and uptake of liberated fatty acids by the perfused 
fat pad from fasted and fed animals. 
chylomicrons 
VLDL 
n 
7 
7 
Results are mean ± SEM 
fasted rats 
hydrolysis % uptake % 
2.0±0.8 
3.6 ± 1.6 
1.0±0.2 
1.2 ±0.2 
fed rats 
hydrolysis % 
14.4± 1S 
4.8± 1.2** 
uptake% 
2.7 ± 0.3* 
0.8±0.2** 
Hydrolysis and uptake are expressed as percentage as described in Materials and Methods 
ted vs. fasted group 
fed vs. fasted group 
VLDL group vs. comparing chylo group 
Table IV 
P<0.001 
p<0.001 
P < O.Q1 
Relationship between heparin-releasab-le and acetone-ether lPl activity on the one 
hand an-d hydrolysis rate and uptake of liberated fatty acids on the other hand, in 
fasted and fed animals. 
condition n TG 0 heparin-releasable acetone-ether hydrolysis 
mM/1 LPL activity LPL activity• (nMoles 
(mU) (mU/gww) FA/pad) 
fasted 7 0.88±0.06 8± 1+ 73± 7 564± 5141> 
fed 7 0.93±0.06 43 ±5+ 249±25 2384± 1860 
Data are expressed as mean± SEM. 
14c-Jabeled chylomicrons were used. End concentration of TG in the perfusion medium is given. 
The acetone-ether LPL activity was determined in the left, non-perfused fat pad 
uptake 
(nMoles/pad) 
130 ± 12 
443±67 
+ Correlation between heparin-releasable LPLactivityand hydrolysisrateinfasted (r= 0.96, p < 0.0005)andfed 
(r = 0.94, p < 0.0002),animals. 
o Correlation between hydrolysis rate of chylomicron·TG and uptake of liberated FA in fasted (r = 0.60) and fed 
(r = 0.53) animals,'P < 0.05. 
DISCUSSION. 
In the present study we applied some modifications to the 
perfusion technique, of the epididymal fat pad as described by 
Ho and Meng (15). Aims were to prevent swelling of the tissue 
and to maintain the adipose tissue in a good condition during 
the procedure. Judged by the ATP content and energy charge of 
the adipose tissue before and after perfusion, the tissue could 
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be kept in a metabolically healthy state for 150 minutes. This 
was accomplished using a flow rate of maximally 100 ~1/min (in 
vivo the flow rate is 70 ~1/g/min>, and a medium containing 
albumin, glucose, insulin, amino acids and red blood cells as 
oxygen carrier. During all experiments we observed a spontaneous 
LPL-release in the perfusion medium. This is also reported by 
Scow et al. (22), but not by Fielding (11). The activity releas-
ed into the medium was in fasted animals about 1 o/oo per minute 
of the total LPL activity in the tissue. In the fed state the 
spontaneous release of LPL activity was 4 - 5 times higher, but 
as a percentage of the LPL activity present in the fat pad the 
same as in fasted animals. Addition of heparin to the medium 
increased the release of the enzyme 20 to 25 times over the 
basal value. LPL activity in adipose tissue can be measured with 
different methods:in a homogenate of an acetone-ether powder or 
after elution of LPL from the adipose tissue by heparin. The 
latter method is believed to reflect the physiologically active 
extracellular enzyme activity. 
Recently we described that in fed rats the enzyme activity after 
heparin elution in vitro was 10 times higher than in the fasted 
animals in contrast to a factor three found in acetone-ether 
powder extracts (2). In the perfusion model of the epididymal 
fat pad this factor was similar (3 to 5) for both the acetone 
ether powder LPL and the heparin-releasable LPL (Fig.1). There-
fore with the in vitro heparin elution method not only the en-
zyme in the vascular compartment appears to be measured. However 
LPL is a labile enzyme and its activity rapidly decreases at 
37°C. In vitro the elution temperature is 30oC, so the diffe-
rence between LPL activity found with the in vitro elution 
method and the in situ perfusion method could also (partially> 
be explained by less loss of activity in vitro. Although the sum 
of the LPL activity released from the endothelium and the re-
maining LPL activity in the fat pad after the perfusion proce-
dure, was equal to the activity extracted from the non-perfused 
fat pad, this does not exclude the possibility of an underesti-
mation of LPL activity during the heparin perfusion. 
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The heparin-releasable pool measured by perfusion of the epidi-
dymal fat pad is 10%-20% of the total pool, in the fasted and 
fed state. This means that a considerable part of newly synthe-
sized enzyme during feeding remains in the non-releasable pool. 
A strong correlation was found between the rate of chylomicron 
TG hydrolysis and the total amount of heparin-releasable LPL in 
the perfusion medium (r=0.94). This once more establish the 
conclusion that the LPL activity in the vascular compartment is 
the physiologically active fraction, especially since chylomi-
cron-TG does not pass the endothelium (22,23). 
In vitro we found that the LPL activity is influenced by the FA 
concentration: the enzyme activity is low using fatty acid-free 
albumin and increased to a maximum when the FA-concentration was 
increased leading to a FA/albumin ratio of 5 : 1. Albumin satu-
rated with FA in the medium did inhibit the LPL activity. In 
the perfusion model of the fat pad with fatty acid-free albumin 
in the medium also no hydrolysis of chylomicrons could be de-
tected. Using albumin with different amounts of fatty acids 
complexed to it, hydrolysis and uptake was present but did not 
change with different FA/albumin ratios. So in situ the re-
lationship between FA-albumin and LPL activity appears less 
important than it seems to be in vitro. One of the possible 
explanations for this difference could be that in the perfusion 
situation the adipose tissue by itself is a FA acceptor too. 
As to the influence of flow rate Scow et al. described a re~ 
lationship with hormone sensitive FFA release from the fat pad, 
but he did not report on an influence of flow rate on chylomi-
cron hydrolysis (22,23). We found a percentual increase of the 
chylomicron hydrolysis if the flow rate was lowered (Table II), 
but the uptake of liberated fatty acids did not increase. In 
fact not the hydrolysis of TG by LPL, but the uptake of FA by 
the adipose tissue appears to be the limiting factor. 
The hydrolysis of chylomicrons and VLDL is low in the fasted 
state (Table III). In fed animals hydrolysis of chylomicron-TG 
had risen, but VLDL-TG hydrolysis did not change. These diffe-
rences were also found for the uptake of the liberated TG-FA. 
This is in line with the general idea that chylomicron-TG is 
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preferentially taken up by adipose tissue and VLDL-TG by muscle 
tissue. However it should be kept in mind that in contrast to 
the chylomicrons used VLDL isolated from plasma has already been 
in contact with LPL. Therefore, the particles isolated may be 
regarded as a less good substrate for LPL. It is difficult to 
compare our results with data derived from in vivo studies on 
the uptake of liberated FA from chylomicron-TG by adipose 
tissue, since the liver is removing most of it after an intra-
venous injection (7,8). However, the uptake of chylomicron-TG-FA 
in perfused adipose tissue in our hands is comparable to that 
calculated by Scow et al. from their experiments with perfused 
parametrial fat (22,23). The uptake of liberated fatty acids is 
correlated with the chylomicron-TG concentration in the medium 
at least up to 4 mM TG; higher concentrations were not used. 
In this study we perfused the epididymal fat pad of the rat 
under standardized, physiological conditions. It is demonstrated 
that for adipose tissue LPL, chylomicrons are a better substrate 
than VLDL. We confirm data from the literature that LPL activity 
in the heparin-releasable compartment strongly correlated with 
chylomicron-TG hydrolysis and less so with the uptake of libe-
rated fatty acids. Only a relatively small part of the LPL 
activity after feeding (activated or synthesized?), is heparin 
releasable. Therefore with the methodology employed, the epidi-
dymal fat pad perfusion seems to be an outstanding model to 
study the regulation, synthesis and transport of lipoprotein 
lipase from the adipocyte to the endothelial compartment. 
so 
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SUMMARY 
Conflicting data have been reported on the influence of (excess) 
glucocorticoids on lipoprotein lipase (LPL) activity in adipose 
tissue. To solve this problem hypercorticism was induced in 
rats by treatment for varying periods with Synacthen, a synthe-
tic corticotrophin-1-24 preparation, and LPL was measured in the 
epididymal fat pads using different methods. In extracts of 
defatted tissue preparations from overnight fasted rats treated 
for 3 days with Synacthen we observed an increase in LPL acti-
vity (acetone-ether powder LPL) to values similar to those found 
in normally fed controls. In contrast, the heparin-elutable part 
of LPL activity in the tissue was. not influenced by the Synac-
then treatment. This activity remained significantly lower in 
overnight fasted animals, whether with Synacthen treated or not, 
than in normally fed rats. Adrenalectomy lowered the acetone-
ether powder LPL activity of the epididymal adipose tissue in 
fasted as well as in fed rats. In fasted rats it prevented the 
stimulation of the LPL activity by Synacthen. 
INTRODUCTION 
Hypercortisolism leads to profound changes in lipid metabolism 
(1,2). Besides an increase in plasma lipid levels (3,4) the fat 
distribution in the body changes. Subcutaneous fat depots are 
depleted and the size of the omental fat stores increases. 
While an increased lipogenesis may contribute to the elevation 
of triglyceride-rich plasma lipoproteins, the mechanisms leading 
to the fat redistribution are not clear. In the rat experimen-
tally induced hypercorticism leads to a situation comparable to 
that found in man. The omental fat tissue reflected in the epi-
didymal fat pad, maintains its weight while the size of the 
subcutaneous fat depots and body weight are lowered (5). 
Lamberts et al. (6) demonstrated a potentiating effect of gluco-
corticoids on the mobilisation of triglyceride in the epididymal 
fat pad of the rat. Since the fat pad weight does not change, an 
increased input of fatty acids into the triglyceride pool of the 
fat pad has to be assumed. These fatty acids can be derived from 
de novo synthesis or from plasma triglycerides taken up after 
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prior hydrolysis under influence of lipoprotein lipase (LPL). 
The activity of this enzyme is generally considered to be the 
rate-limiting factor in the uptake of serum triglycerides. Some 
investigators found a decrease in LPL activity in the adipose 
tissue of rats during hypercorticism <7-10). Others however 
found an opposite effect (11). In humans no difference between 
adipose tissue LPL activity of patients with Cushing's syndrome 
and controls was found (12). These conflicting results may have 
been caused by several factors: different methods for the in 
vitro LPL assay have been used, studies have been .conducted in 
fed and fasted animals treated for different periods with diffe-
rent hormone preparations. Moreover the genesis of the Cushing's 
syndrome ~aries (pituitary adenoma with raised corticotrophin 
levels or .-cortisol secreting adrenal tumors with suppression of 
corticotrophin secretion). To study to what extent these various 
factors can contribute to the differential effects on LPL ob-
served we made rats hypercorticistic using a corticotrophin 
analogue for varying periods of time and measured the LPL acti-
vity of the epididymal fat pad with different methods in intact 
and adrenalectomized rats. 
MATERIALS AND METHODS 
Male rats of the Wistar strain with a weight of 200-250 g were 
used. The rats had free access to standard lab chow and tap 
water unless noted otherwise. To assure survival for a short 
period adrenalectomized rats received 0.9% NaCl (w/v) in the 
drinking water. Lights were on from 8.00 a.m. till 6.00 p.m. 
Hypercorticism was induced by daily subcutaneous injections in 
the suprascapular region with 50 ug (= 5 I.U.) of a synthetic 
1-24 corticotrophin <Synacthen depot, Ciba Geigy NV, Belgium). 
Treatment was for 3 or 20 days. The drug was administered late 
in the afternoon. This regimen leads in intact rats to hypercor-
ticism with plasma corticosterone levels of 610 ± 137 ng/ml vs. 
258 ± 120 ng/ml in the controls (13). For each experimental 
condition 6 animals were used. The control groups were injected 
with 0.9% NaCl (w/v). The fasted groups were deprived of all 
caloric intake 16 hours before use. The rats were killed by 
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decapitation between 9.00 and 10.00 a.m. The blood was collected 
in ice-cooled tubes containing 10 mg Na2 EDTA. Half of the right 
epididymal fat pad was defatted with acetone and diethyl-ether 
as described by Nilsson-Ehle et al. <15). (acetone-ether 
powder). LPL activity was measured in Tris-ethylene glycol 
buffer extracts <1-3 mg powder/ml) on the same day <14,15). This 
activity is referred to as acetone-ether powder LPL activity. 
The other half of the fat pad was cut into pieces of about 20 
mg, and placed into 10 ml medium consisting of Krebs-Ringer 
buffer (pH: 8.3), supplemented with albumin (5% w/v, bovine 
serum albumin, Fraction V, Sigma St.Louis, USA>, heparin (50 
IU/ml, Tromboliquine, Organon, Oss, The Netherlands) and glucose 
(5mM). After incubation for 40 minutes at 30oC in a shaking 
water bath, the tissue was removed and 100 ~1 of the medium was 
incubated with an equal amount of a substrate mixture to measure 
LPL <Heparin-elutable LPL (16)). The LPL substrate consisted of 
a glycerol stabilized glycerol-tri 9,10(n)-3H-oleate, phospho-
lip.id emulsion as described in detail by Nilsson-Ehle et al. 
<15). The activity is expressed in milli Units <nmoles free 
fatty acid released per min). Serum of overnight fasted male 
rats served as LPL activator. Insulin (IRI> was measured with a 
I125 radioimmunoassay (Insulin RIA, Immuno Nuclear Cooperation, 
Stillwater, Minn, USA ). The statistical significance of diffe-
rences between groups was calculated comparing each experimental 
group with its control group using the unpaired Student's t-
test. 
RESULTS 
"Physiological" effects of Synacthen treatment. 
Synacthen administration affected body- and adrenal weight, but 
not the weight of the epididymal fat pads. Water intake in the 
several experimental groups was similar. Food intake was lower 
in the adrenalectomized rats than in the non-adrenalectomized 
controls and Synacthen treated rats. (Adrenenalectomized rats: 
13 g per day, controls: 20 g per day and Synacthen treated rats: 
19 g per day per rat). There was no difference in food intake by 
the rats treated with Synacthen for 3 or 20 days. The adrenal 
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Table 1. Effect of Synacthen on Body, Epididymal Fat Pad, and Adrenal Weight in Rats• 
Feeding 
Condition 
Fasted-Q-
Fed 
Intact/ 
adxt 
Intact 
intact 
intact 
intact 
adx 
adx 
intact 
intact 
intact 
intact 
adx 
adx 
Treatment Duration of 
Saline/Synacthen treatment (d) 
Saline 3 
Synacthen 3 
Saline 20 
Synacthen 20 
Saline 3 
Synacthen 3 
Saline 3 
Synacthen 3 
Saline 20 
Synacthen 20 
Saline 3 
Synacthen 3 
Body Weight 
(g) 
214±3 
199±10 
275±12 
183±16 
1g2±9 
190±18 
233 ± 14 
209±11 
282 ± 13 
198±8 
176±5 
186 ± 11 
Epididymal 
Fat Pad (mg) 
1,417 ± 160 
1,556 ± 188 
1,614±288 
1,728±315 
763 ± 164 
988±372 
1,034±202 
813±113 
1,651 ±303 
1,580±401 
470±46 
533±156 
Adrenals 
(mg) 
30±3 
64±5 
27±3 
104± 18 
27±2 
64±10 
25±3 
121 ± 12 
• rats were adrenalectomized ten days before starting Synacthen injections, which they received for three days. 
t adx; bilateral adrenalectomized. 
-Q- rats were fasted for 16 hours before being killed. 
Insulin 
,uU/mL 
7.8±4.7 
20.6 ±8.4 
10.1 ± 2.0 
22.7±5.6 
NO 
NO 
25.0±3.7 
45.3±7.8 
22.7±2.9 
40.7±4.4 
NO 
NO 
weight showed an increase up to 4-5 times the basal value. Insu-
lin levels were elevated after three days of Synacthen treatment 
and did not change during further Synacthen treated fasted rats 
and in the normally fed controls insulin levels were similar. 
Synacthen treatment induced a further increase (Table I> of 
insulin levels in the fed state. 
Lipoprotein lipase activity in control, Synacthen-treated and 
adrenalectomized rats. 
LPL activity in epididymal fat pads was measured in rats treated 
with Synacthen with or without prior adrenalectomy. Adrenalec-
tomy led to a lowered acetone-ether powder LPL activity in nor-
mally fed and overnight fasted rats (Table II). Upon Synacthen 
administration the LPL in overnight fasted intact animals was 
increased nearly to the values measured in normally fed con-
trols. This effect was completely abolished by adrenalectomy. In 
normally fed rats no further (significant) increase in the LPL 
activity during Synacthen induced hypercorticism was observed. 
In normally fed rats acetone-ether powder LPL activity was after 
adrenalectomy comparable to that found in overnight fasted in-
tact rats. 
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Table II. Effect of Synacthen·Administration for 3 Days and/or 
Adrenalectomy on Acetone-Ether Powder lipoprotein lipase 
Activity in Normally Fed and Overnight Fasted Rats 
Treatment lipoprotein l,.ipase (mU/g wet weight) 
Saline 
Saline and adrenalectomy§ 
Synacthen 
Synacthen and adrenalectomy 
Fasted Rats Fed Rats 
84±15t 
48±13 
140±251:. 
65±35 
150±47* 
81 ±16 
180 ± 11 
94±33 
• significantly different from the fasted untreated group (p < 0.02) and adrenalectomized groups. 
t significantly different from the fasted adrenalectomized group (p < 0.05). 
-(; significantly different from the untreated tasted group (p < 0.001). 
§ rats were adrenalectomized ten days before starting Synacthen treatment. 
LPL activity in control and Synacthen treated rats determined 
with different methods. 
When measured with the heparin-elution method the LPL activity 
in normally fed rats was much higher than with the acetone-ether 
powder method. In fasted animals the opposite was found (compare 
Tables III and IV). This resulted in a fed/fasted ratio of LPL 
activity of about two with the acetone-ether method and of more 
than ten with the heparin-elution method. 
Table Ill. Effect of Synacthen Treatment on Acetone-Ether Powder lPl Activity of the 
Epididymal Fat Pad in Normally Fed and Overnight Fasted Rats* 
lipoprotein lipase (mU/g wet weight) 
Treatment Duration of 
Saline/Synacthen Treatment {d) Fasted Fed 
Saline 3 84±15 150±471:. 
Synacthen 3 140 ± 25t 180 ± 11 
Saline 20 105±26 133 ± 34 
Synacthen 20 133±61 143±81 
• The mean LPL activities ± SO are given for different periods of Synacthen treatment. Each experimental 
group consisted of six animals in the fasted and four animals in the fed state. 
t significantly different from the untreated fasted group (p < 0.001). 
*significantly different from the untreated fasted group (p < 0.02). 
After Synacthen treatment for 3 days the acetone-ether powder 
LPL activity was 66% higher than in non-treated controls if 
the rats were fasted overnight prior to use. The LPL activity 
was then comparable to that in normally fed controls. After 20 
days the difference in LPL between Synacthen-treated and non-
treated fasted rats was much less (27%) and statistically not 
significant. The increase in LPL after three days of Synacthen 
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treatment was not found if the rats were not fasted overnight 
(Table III). With the heparin-elution method no change in LPL 
activity was found after treatment with Synacthen of fasted or 
fed rats <Table IV). 
Table IV. Effect of Synacthen Treatment on Heparin Elutable LPL Activity of the 
Epididymal Fat Pad in Normally Fed and Overnight Fasted Rats* 
lipoprotein lipase (mU/g wet weight) 
Treatment Duration of 
Saline/Synacthen Treatment (d) Fasted Fed 
Saline 3 29±7 444± 102t 
Synacthen 3 24± 12 464± 164t 
Saline 20 28±7 382±75 
Synacthen 20 19±9 317±160 
• The mean LPL activities are given ± SD for different states and periods of Synactren treatment. Each 
experimental group consisted of six animals in fasted and four animals in fed state. 
t significantly different from the fasted group (p < 0.001). 
DISCUSSION 
The role of LPL in the uptake of fatty acids derived from tri-
glycerides in the blood (TG-FA) by adipose tissue has received 
considerable interest during the past twenty years (17-20). 
Chylomicrons and very low-density lipoproteins <VLDL) are hy-
drolyzed by LPL at or close to the surface of the endothelial 
cells of the blood capillaries so that free fatty acids (FFA) 
are generated. The FFA can enter the fat cells to be reesteri-
fied and stored as TG. The mobilisation of FFA from endogenous 
TG pools in isolated fat cells derived from the epididymal fat 
pad of rats pretreated with glucocorticoids (6,21,22) is enhanc-
ed. The net effect of this treatment on the fat pad weight is 
dependent on the de novo synthesis of FA in the adipocytes and-
/or by the flux of FFA from plasma TG into the fat cells. Lau 
and Roncari (23) found a decreased fat pad weight and a lowered 
activity of lipid synthesizing enzymes in adipocytes after 
treatment of rats with dexamethasone, while others have descri-
bed a decreased activity of LPL in the epididymal fat pad after 
administration of glucocorticoids. In some studies (5,14) pre-
treatment of rats with glucocorticoids had no effect on the 
epididymal fat pad weight. If the intracellular lipolysis is 
increased under these conditions then an increased de novo 
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synthesis and/or increased FFA uptake should occur to compensate 
for the loss of FFA from the tissue. We studied the effect of 
excess glucocorticoids on LPL activity by treatment of rats with 
Synacthen, a synthetic corticotrophin analogue. We found no 
significant changes of fat pad weight in the fasted nor in the 
fed state, even during long-term hypercorticism. Adrenalectomy 
led to a pronounced decrease in body- and fat pad weight, which 
was not prevented by Synacthen treatment. In fasted Synacthen-
treated rats we consistently found a LPL activity elevated to 
the level in normally fed controls. This effect was already seen 
after 3 days of treatment. Adrenalectomy resulted in a pronounc-
ed (about 50%) reduction in LPL activity. 
LPL is probably synthesized in the fat cell. Its synthesis is 
stimulated by insulin and glucocorticoids <24). After synthesis, 
the enzyme is transported to the luminal side of the endothelial 
cells, where it is assumed to exert its function, and is attach-
ed to heparan sulphate lining the vessel wall (20). Heparin with 
a st.ructural analogy to heparan sulphate can release LPL from 
its binding site. Following elution of the enzyme with heparin 
one can measure LPL activity in the cell-free eluate. It is 
generally assumed that this heparin-elutable LPL represents the 
physiologically active form of the enzyme (25). Using another 
method, the acetone-ether powder method, it is suggested that 
the intracellular LPL pool is measured in addition to the 
elutable enzyme. We found no effect of Synacthen treatment on 
heparin-elutable LPL activity, in the fasted nor the fed state. 
However, as discussed above, the LPL activity in the acetone-
ether powders of the tissue turned out to be higher at least in 
animals in the fasted state. This increase is probably caused by 
an enhanced synthesis of the enzyme and is apparently confined 
to a pool, which is not elutable by heparin in vitro. Insulin 
may stimulate the synthesis of LPL in the adipocyte. During 
Synacthen treatment a pronounced hyperinsulinemia develops in 
the fasted groups comparable to those of the normally fed con-
trols. In spite of a further increase of the insulin level in 
the fed Synacthen-treated animals no further increase in LPL 
activity was observed. It is possible, therefore, that the 
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capacity to synthesize the enzyme is utilized maximally in the 
fed controls and fasted treated rats. The discrepancy in be-
haviour of acetone-ether powder and heparin-elutable LPL acti-
vity to glucocorticoid excess suggests that the synthesis of the 
enzyme in the adipocyte is stimulated during pretreatment with 
Synacthen, while the transfer to the endothelial cell is impair-
ed. Our results demonstrate once more the necessity to evaluate 
these two frequently applied methods for determining LPL acti-
vity in respect to their physiological significance. 
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SUMMARY 
Rats were treated with Synacthen, a synthetic corticotrophin 
analogue, to induce hypercorticism. The epididymal fat pad was 
selectively cannulated and perfused. 
In fasted rats acetone ether powder lipoprotein lipase (LPL) 
activity rose during treatment to levels found in fed controls. 
In fed animals no further rise in LPL activity was observed 
during Synacthen treatment. However, the heparin-elutable LPL 
activity did not change in fasted nor fed animals. Pharmacologic 
levels of insulin in the perfusion medium, caused an increase in 
heparin releasable LPL activity as a percentage of total fat pad 
LPL activity <15% vs 48 %). 
Hydrolysis of chylomicrons was higher in fasted three days 
treated animals than in controls (10 ± 4% vs 2 ± 2%). In this 
group a higher uptake of liberated free fatty acids was found 
(2.6 ± 1.5% vs 1.0 ± 0.5% in controls). The increase in hydroly-
sis rate and uptake of fatty acids in the treated fasted animals 
could not be explained by an increase in releasable LPL activi-
ty. 
Fatty acid release from the fat pad was lower in treated animals 
than in controls <fasted and fed), basally as well as after 
adrenalin stimulation. The observation that the epididymal fat 
pad retains its weight during hypercorticism may therefore be 
ascribed to an increased influx of fatty acids from increased 
hydrolysis of TG-rich particles and to an inhibited efflux of 
fatty acids from the adipocyte. The discrepancy between the LPL 
activity extractable from an acetone ether powder and the hepa-
rin-releasable LPL activity suggests impairment of the transport 
of LPL from the adipocyte to the heparin releasable pool at the 
endothelium. 
INTRODUCTION 
Hypercorticism leads to profound changes in lipid metabolism, 
and is associated with a characteristic centripetal redistribut-
ion of fat in humans. Rats do not have this typical redistribut-
ion of adipose tissue, but it is suggested that glucocorticoids 
have differential effects on the weight of different adipose 
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depots Cl). In hypercorticistic rats total body.weight is 
decreased while the weight of the epididymal fat pad is main-
tained C2,3). 
The influence of glucocorticoids on adipose tissue has been 
studied in isolated fat cells (2,4-6). Glucocorticoids are 
either necessary for or markedly increase the effect of stimuli 
of hormone sensitive lipase in adipose tissue <2,4-10). There-
fore the effect of glucocorticoids, if unopposed, is to increase 
lipolysis, resulting in free fatty acid release. 
In the intact organism the lipolytic action of glucocorticoids 
is counteracted by insulin. The typical distribution of fat in 
humans, and the preservation of the epididymal fat pad in the 
rat, associated with excess levels of glucocorticoids may be 
due to the fact that the insulin response predominates in the 
regions of increased fat mass, and that the direct steroid res-
ponse predominates in the areas of fat loss (6). Trying to elu-
cidate part of this problem we made rats hypercorticistic by 
treating them with Synacthen, a synthetic corticotrophin analo-
gue, and found an increase in tissue LPL activity in the treated 
animals (3). LPL is the rate limiting enzyme in the hydrolysis 
of triglycerides (TG) from chylomicrons. To study the effect of 
glucocorticoids on the handling of exogenous lipid by the fat 
pad, we perfused epididymal fat pads in vitro (11) and studied 
the hydrolysis and uptake of chylomicron-triglycerides under 
different conditions. In addition the effect of glucocorticoids 
on adrenalin stimulated lipolysis was determined. 
MATERIALS AND METHODS 
Male rats of the Wistar strain with a weight of 200-250 g 
were used. The rats had free access to standard lab chow and tap 
water. Lights were on from 09.30 a.m. to 9.30 p.m. Hypercorti-
cism was induced by daily subcutaneous injections of 50 ~g (= 5 
I.U.) of synthetic 1-24 corticotrophin <Synacthen depot, Ciba 
Geigy, Belgium)in the suprascapular region. Treatment was for 3 
or 10 days. The drug was administered late in the afternoon. In 
intact rats this regimen leads to hypercorticism with plasma 
corticosterone levels of 610 ± 137 ng/ml vs. 258 ± 120 ng/ml in 
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control rats (12). For each experimental condition four animals 
were used, unless noted otherwise. 
The control groups were injected with 0.9% NaCl (w/v). The fas-
ted groups were deprived of all caloric intake 16 hours before 
use. Rats were used for perfusion between 09.30 and 10.00 a.m. 
Perfusion of the epididymal fat pad was carried out for 60 min 
according to Ho and Meng (13) extensively modified by us (11; 
chapter II). Where noted insulin (Actrapid NOVO, Copenhagen, 
Denmark), adrenalin or heparin were added to the perfusion 
medium. 
Chylomicrons labeled with 14c-palmitate were prepared as de-
scribed earlier (11; chapter II,14). Extraction of fatty acids 
and triglycerides from the perfusate occurred according to Bligh 
and Dyer <15). Subsequently thin-layer chromatography was per-
formed. The specific activity of TG-FA ranged from 0.95 to 1.09 
x 106 dpm/~mol TG. 
Hydrolysis of chylomicron-triglycerides was expressed as the 
quotient of the increament in radioactive free fatty acids and 
the total radioactivity in the TG fraction (100 x delta dpm FA/ 
dpm TG-FA =%hydrolysis). 
The uptake of fatty acids in the perfused fat pad was calculated 
as the ratio of radioactivity accumulated in the fat pad and the 
total radioactivity, that passed through the pad during perfu-
sion. LPL activity was determined in defatted preparations 
(acetone-ether powder) of the fat pad (16,17> and in the medium 
after perfusion. The LPL substrate consisted of a glycerol 
stabilized glycerol-tri 9,10 (n)-3H-oleate, phospholipid 
emulsion as described in detail by Nilsson-Ehle et al. (16). 
RESULTS 
LPL activity and plasma TG during Synacthen treatment. 
As previously observed during Synacthen treatment (3) LPL acti-
vity increased significantly in acetone-ether extracts of the 
epididymal fat pad of fasted rats <Table I; p < 0.02) and was 
not significantly different from the activity in the fed groups, 
either treated with Synacthen or not. Plasma TG concentration 
was not changed by the treatment in the fasted animals. The 
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Table 1. Lipoprotein lipase Activity in the Epididymal Fat Pad and Plasma Triglyceride 
Concentrations in Controls and Synacthen·Treated Rats 
Feeding Treatment Duration of TG LPle 
Conditions Group n (Saline/Synacthen) Treatment (d) (mmol/l} (mU/gww) 
Fasted I 7 Saline 10 0.65 ±0.11 97±39t 
II 7 Synacthen 3 0.63±0.09 390± 190* 
Ill 7 Synacthen 10 0.62 ±0.14 240 ±57§ 
Fed IV 7 Saline 10 1.28 ±0.30 440± 158 
v 7 Synacthen 3 2.40 ±0.47 378±81 
VI 7 Synacthen 10 1.92 ±0.92 436± 140 
• Measured in the nonperfused epididymal fat pad. 
t Significantly different from group IV (p < .01). 
* Significantly different from group I (p < .02). 
§ Significantly different from group I (p < .05). 
Group II and Ill v IV; IV v V and VI are not significantly different. 
Synacthen treated fed rats were hypertriglyceridemic. 
Effect of insulin on heparin-releasable LPL activity. 
To study the possible underlying cause for the observed discre-
pancy between the increase in total and heparin-releasable LPL 
we determined the effect of a relatively low (100 ~U/ml> and 
high (10 mU/ml> insulin concentration on the distribution of LPL 
over heparin-releasable and non-releasable pools. In fasted rats 
treated for 3 days with Synacthen the low insulin concentration 
did not affect the heparin-releasable activity but with the high 
insulin concentration a significantly <p < 0.01> higher lipase 
activity was found (Table II). This suggests that insulin in 
high doses in Synacthen treated rats promotes the transport of 
LPL to the heparin-releasable pool. 
Effect of Synacthen treatment on the hydrolysis of chylomicron--
TG and uptake of chylomicron-TG-FA in perfused epididymal fat 
pad. 
The impact of changes in LPL activity during Synacthen treatment 
on the hydrolysis and uptake of chylomicron-TG-FA were studied. 
Hydrolysis of chylomicron-TG in fasted untreated animals is low: 
5-7 times lower than in the fed controls (Table III). In the 
three and ten days treated and fasted rats hydrolysis of 
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chylomicrons rose significantly Cp < 0.001 and < 0.05, 
respectively>. 
Table II. Heparin-Releasable LPL Activity in Controls and Synacthen-
Treated Fasted Rats With Two Different Insulin Concentrations in 
the Perfusion Medium 
Insulin 
0.1 mU/ml 
10 mU/mL 
n 
4 
4 
Controls 
8±4 
15± 11* 
n 
4 
4 
Synacthen 
15 ± 11 
48±14t 
LPL activity is given as percentage of the acetone-ether extractable LPL of the non-perfused 
fat pad. 
* NS v the low insulin concentration group. 
t Significantly different from all other groups p < .01. 
Table Ill. Effect of Synacthen Treatment on the Hydrolysis of 
Chylomfcron-TG in the Perfused Epididymal Fat Pad of the Rat 
n Fasted n Fed 
0 7 2±2 7 14±4* 
3 7 10±4t 7 15±3 
10 7 7±2>'r 7 12±5 
Hydrolysis is expressed as the percentage of labeled fatty acids freed from the labeled 
TG-FA during the whole of the perfusion (60 minutes). 
* Significantly different from the untreated fasted group (p < .001) 
t Significantly different from the untreated fasted group {p < .001) 
1:r Significantly different from the untreated fasted group (p < .05) 
In the untreated groups heparin-releasable LPL activity and 
hydrolysis rate were significantly correlated Cr = 0.9, n = 7). 
In contrast in none of the Synacthen treated groups a corre-
lation was observed. 
The effect of Synacthen treatment on the uptake in the perfused 
tissue was similar to that on hydrolysis of chylomicron-TG 
(Table IV). A significant increase in uptake in the fasted 
animals treated with Synacthen for three and ten days was found 
Cp < 0.05), resulting in a percentage of uptake identical to 
that found in the fed controls. 
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Table IV. Effect of Synacthen Treatment on the Uptake of Chylomicron· 
Fatty Acids in the Perfused Epididymal Fat Pad 
0 
3 
. 10 
7 
7 
7 
Fasted 
1.0 ±0.5 
2.6 ± 1.5* 
3.3 ± 1.6* 
7 
7 
7 
Fed 
2.7 ± 0.9t 
3.2 ±0.8 
3.2 ±0.9 
Uptake is expressed as percentage of TG·FA that has been extracted from the perfusate. 
*Significantly different from the untreated fasted group (p < .05) 
tSignificantly different from the untreated fasted group (p < .05). 
Effect of adrenalin on FA release from the fat pad from 
Synacthen treated rats. 
Besides uptake of FA, release of FA may determine the size of 
the fat body. Therefore the extend of adrenalin stimulated 
lipolysis was measured in Synacthen treated animals. In the 
absence of adrenalin FA release from the fat pad in fasted 
controls was significantly higher than in fed ones (p < 0.02). 
During prolonged perfusions without adrenalin in the medium 
FA-release did not change in both situations. After adding 
adrenalin to the medium (1 ~g/ml) FA release was largely 
stimulated in both fasted and fed animals (Fig. 1). Fed pads 
of Synacthen treated rats released significantly less fatty 
acids in both conditions than those of the controls (Fig. 1). 
DISCUSSION 
Hypercorticism in rats induced by daily injections of Synacthen 
leads to an increase in adipose tissue LPL activity in acetone 
ether powder extracts of the fat pad. However, the in vitro by 
heparin-incubation releasable lipase activity remains unaltered 
(3). It is generally assumed that the last mentioned activity 
represents the physiologically active enzyme pool. In hypercor-
ticistic rats and in controls the fat pad weight is similar 
(2,3) while it has been reported that in the adipocyte gluco-
corticoids have a potentiating effect on the intracellular adre-
nalin stimulated lipolysis (6), an increased input of FA into 
the TG pool of the fat pad has to be assumed. However, as dis-
cussed above the physiologically active LPL pool seems not to 
be enhanced. To study this apparent discrepancy we induced hy-
percorticism in rats by Synacthen treatment and carried out a 
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Fig 1. Effect of adrenaline on fatty acid release from the fat pad in the perfusate in controls 
and Synacthen·treated animals. Data are given as mean± SEM. Perfusion during 60 minutes 
was carried out in fasted (A) and fed (B) animals; controls (_) and Synacthen·treated (- • -) 
animals. Synacthen treatment with 5 IU sc for three days. After ten minutes perfusion, 
adrenaline (1 !Lg/ml) was added to the medium(!).* Significantly different from the untreated 
group P < .05. o Significantly different from the untreated group P < .02. 
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selective perfusion of the epididymal fat pad. 
However in the hypercorticistic rats, the heparin-releasable LPL 
activity in the perfusate rose from 3 ± 1 to 12 ± 8 mU in fasted 
animals. In fed animals the heparin releasable pool of LPL in-
creased to 36 ± 20 mU in controls, while Synacthen treatment did 
not further increase this pool (30 ± 13 mU). This is in contrast 
to the lack of influence of Synacthen treatment on the heparin-
elutable LPL activity in in vitro experiments (3). This increase 
may explain the observed rise in TG-hydrolysis in situ and the 
increase of the uptake of TG-FA. In controls hydrolysis of chy-
lomicron-TG correlated strongly with the heparin releasable LPL 
activity in the perfusate. Such a correlation was not found in 
the hypercorticistic animals, although it seems that a correla-
tion is present between acetone-ether LPL and TG-hydrolysis. 
Hydrolysis rate in the short-term Synacthen treated and fasted 
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animals, was significantly higher than in the fasted controls 
and approached the level found in fed controls. We cannot easily 
explain why the increased hydrolysis did not correlate with the 
heparin-releasable LPL activity. It seems that not under all 
conditions LPL is the only or major determinant of the hydroly-
sis of chylomicron-TG. In line with this observation Verschoor 
et al. (18> reported that diet induced changes in adipose tissue 
LPL activity (acetone-ether powder and heparin-elutable> did not 
furnish any useful information about VLDL-TG kinetics. It is 
possible that Synacthen treatment induces changes in the enzyme 
configuration lowering the Km of the enzyme for chylomicrons 
leading to a higher rate of hydrolysis with a given in vitro LPL 
activity (capacity). The increase in hydrolysis of chylomicrons 
in short-term treated and fasted rats leads to an increase in 
uptake of FA by the epididymal pad to levels found in the fed 
ones. Therefore, apparently hypercorticism leads in situ to an 
increase of the FA uptake by the adipose tissue. The discrepancy 
in chylomicron hydrolysis and FA-uptake indicates a dissociation 
between the capacity of the epididymal fat pad to hydrolyze and 
esterify FA under the influence of Synacthen. In other words the 
hydrolysis is stimulated by Synacthen to a greater extent than 
the uptake. 
The increased FA influx into the adipocyte from the vascular 
compartment alone cannot explain the retaining of the pad weight 
during hypercorticism for prolonged periods. The data represen-
ted in Fig. 1 show that the FA release from the adipocytes into 
the vascular compartment was reduced in the Synacthen treated 
rats, both in the fasted and fed state. This lowering effect was 
more pronounced during stimulation of the intracellular lipo-
lytic process with adrenalin. These findings are in contrast 
with experiments in isolated epididymal adipocytes from fasted 
rats in which pretreatment of the animal with cortisol lead to a 
further increase of the adrenalin induced lipolysis (6). This 
remarkable discrepancy may be explained by the fact that in vivo 
(or in situ) the secondary hyperinsulinism in hypercorticistic 
rats counteracts the increased intracellular lipolysis. This 
results in an increase in total LPL content of the adipose 
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tissue (acetone-ether powder LPL activity is presumed to reflect 
total tissue enzyme> an increase of the FA uptake and a decrease 
of the intracellular lipolysis leading to a balanced state in 
which the fat pad can retain its weight. 
Spirovski et al. (19) who studied lipolysis in the perfused 
parametrial fat of the fed rat, found an increased reesterifica-
tion in intact and adrenalectomized Synacthen treated animals. 
Although the results of the present study do not contradict 
those of Spirowski et al. (19>, the conditions in our experi-
ments are different to such a degree that it makes comparison 
difficult. 
Synacthen treatment in fasted rats leads to a marked increase in 
LPL activity in acetone-ether powders of the adipose tissue, a 
(slight) increase in heparin-releasable LPL (Table III) but not 
to changes in the heparin-elutable LPL activities in vitro (3). 
These data may indicate a situation in which the enzyme is con-
fined to a pool not elutable by heparin in vitro or in situ. 
In hypercorticistic rats a pronounced hyperinsulinemia develops 
in the fastirg state. The insulin levels become comparable to 
that of the normally fed controls. Many studies have shown that 
insulin administration leads to a rise in LPL in adipose tissue 
(18,20,21). In the tissue culture insulin stimulates the release 
of LPL from adipocytes (22-24). There is evidence that the insu-
lin effect on enzyme synthesis is enhanced by glucocorticoids in 
vitro (25). Possibly the synthesis of LPL in adipose tissue of 
hypercorticistic rats is maximal, but the transfer of LPL to the 
endothelial cell is impaired. To study whether a relative 
shortage of insulin (insulin resistance) may have contributed to 
an impaired transfer of LPL to the heparin releasable pool we 
added pharmacologic insulin concentrations <10 mU/ml> to the 
perfusion fluid in Synacthen treated and control fasted rats to 
overcome possible blockade of the transport of LPL from the 
adipocyte to the vascular compartment. Under these conditions 
the heparin releasable LPL rose from 15% to 48% of total LPL 
activity measured in the fat pad of the Synacthen treated rats. 
In these experiments with insulin added to the perfusion medium, 
insulin appeared to cause a shift of LPL from the intracellular 
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to the heparin-releasable pool, while the total enzyme activity 
(the sum of the heparin-released LPL and the remaining activity 
in the perfused pad) did not change. 
The results of these in situ experiments confirm the hypothesis 
that the transport of LPL from intra- to extracellular loci in 
adipose tissue is insulin dependent <24,25). More detailed stu-
dies of this transport system and of the effects of insulin, 
glucocorticoids and other hormones thereon are in progress. 
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LIPOPROTEIN LIPASE IN RAT ADIPOSE TISSUE. 
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SUMMARY 
The effects of corticosterone and ACTH (1-24) on lipoprotein 
lipase (LPL) activity of rat epididymal fat tissue were studied. 
Hypercorticism induced by s.c. administration of 10 mg cortico-
sterone acetate for 3 days led to a decrease in LPL activity. 
This decrease could be prevented by treatment of the rats 
simultaneously with synthetic ACTH (1-24). Adrenalectomy also 
reduced LPL activity. Corticosterone and ACTH (1-24) treatment 
had a similar effect on LPL activity in adrenalectomized and 
intact rats. 
These results indicate that ACTH (1-24) may affect adipose 
tissue LPL in the rat by a mechanism in which corticosterone is 
not involved. 
INTRODUCTION. 
Lipoprotein lipase <EC 3.1.1.34> is the enzyme that catalyses 
the hydrolysis of triacylglycerols in chylomicrons and very low-
density lipoproteins. In adipose tissue the enzyme is synthesiz-
ed in the adipocytes from which it is secreted and transported 
to the luminal surface of the capillary endothelial cells were 
it exerts its effect (1,2). Environmental changes lead to large 
variations in the activity of the enzyme, and many of these 
variations are under hormonal control (3). There is good eviden-
ce, for example, that insulin promotes the synthesis of the 
enzyme in the adipocyte. The role of corticosteroids in the 
regulation of lipoprotein lipase activity (LPL) is less clear. 
Some investigators have reported an increase in LPL activity 
after the administration of corticosteroids to rats (3,4), while 
others have found an opposite effect (5-8). We have previously 
described an increase in total LPL activity in the epididymal 
fatpad of the rat during short- and long-term hypercorticism 
induced by Synacthen, a synthetic corticotrophin (1-24) <ACTH 
1-24) preparation {9). However, LPL activity which could be 
released £rom the tissue by heparin and which probably 
represents the functional pool of the enzyme was not influenced 
by this treatment. In this paper we report further studies on 
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the effects of ACTH (1-24) and corticosterone on LPL activity in 
the epididymal fat pad of the rat. 
MATERIALS & METHODS. 
Animals. 
Male rats of the Wistar strain weighing of 200 to 250 g were 
used. They had free access to standard lab chow and drinking 
water unless noted otherwise. To ensure survival for a short 
period, adrenalectomized rats received 0.9% NaCl (w/v) in their 
drinking water. Lights were on from 9.30 till 21.30. Some rats 
were adrenalectomized ten days before starting treatment. 
Treatments. 
Corticotrophin <1-24) <Synacthen depot, Ciba Geigy, Brussels, 
Belgium) was administrated for three days by daily subcutaneous 
injections in the suprascapular region (50 ~g; 5 I.U.per animal 
per day). In addition, or alternatively, various doses of cor-
ticosterone 21-acetate (Sigma, St. Louis, MO, USA;l, 5 or 10 mg 
per animal) were given. All treatments were administered late in 
the afternoon. The control groups were injected with 0.9% (w/v) 
NaCl. The fasted groups were deprived of all food for 16 h be-
fore use. Rats were killed by decapitation between 9.30 and 
10.30 h. 
Biochemical methods. 
Blood was collected in ice-cooled tubes containing 10 mg Nq2-
EDTA. The right epididymal fat pad was defatted with acetone and 
diethyl-ether as described by Nilsson-Ehle & Schatz <10). acti-
vity was measured in Tris-ethylene glycol bufier extracts of 
the defatted tissue <1-3 mg powder/ml) on the same day (10,11). 
This activity is referred to as acetone-ether powder LPL acti-
vity. The left pad was cut into pieces of about 20 mg and placed 
in 10 ml medium consisting of Krebs-Ringer buffer (pH 8.3), 
supplemented with bovine serum albumin (5% w/v, fraction V, 
Sigma, St. Louis, USA), heparin (50 I.U./ml; Tromboliquine, 
Organon, Oss, The Netherlands), glucose (5 mmol/1). After incu-
bation for 40 min at 30oC in a shaking water bath, the tissue 
was removed and 100 ~1 medium were incubated with an equal 
amount of a substrate mixture to measure LPL activity 
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Table 1. Effect of corticosterone treatment on lipoprotein lipase (LPL) activity 
in adipose tissue and on plasma hormone concentrations in normally fed rats 
and in rats fasted overnight. Values are means± S.E.M. for four rats per group. 
Treatment 
Fasted rats 
Saline 
Corticosterone ( 1 mg) 
Corticosterone ( · 5 mg) 
Corticosterone (1 0 mg) 
Fed rats 
Saline 
Corticosterone ( 1 mg) 
Corticosterone ( 5 mg) 
Corticosterone (1 0 mg) 
Acethone·ether Heparin· 
powder LPL** elutable LPL••• Insulin 
(mu./g wet wt) (mu./g wet wt) (pmol/1) 
75±9 53±5 60.9±4.9 
56±9 36±3 63.3±7.7 
51 ±5 29±3 73.5±4.9 
43±6* 19±5* 105±9.1* 
322±38 288±39 126.0 ± 14.0 
224± 19 352±57 119.0±2.1 
224±19 336±47 182.0±26.6 
181 ±22* 198 ± 25 217.0±26.6* 
Corticosterone 
(ng/ml) 
192±70 
190±85 
281 ±75 
506±35* 
150±75 
110±80 
288±80 
415±79* 
* p < 0.025 compared with control (saline) group {unpaired Student's t-test); **Lipoprotein lipase activity 
measured in an extract from the defatted epididymal fat pad;*** lipoprotein lipase activity measured in a heparin-
containing medium after a 40-min incubation of pieces of the epididymal fat pad. 
<heparin-elutable LPL) (12). The substrate mixture for the LPL 
measurement consisted of a glycerol-stabilized glycerol-
-tri[9,10-3HJ oleate-phospholipid emulsion. (10). The activity 
is expressed in milli Units <mU; nmol fatty acid released per 
min) per gram tissue wet weight. Serum from male rats, which 
had been fasted overnight, served as the LPL activator. Insulin 
(IRIJ was measured with a 125I radioimmunoassay <Insulin RIA; 
Immune Nuclear Cooperation, Stillwater, MN. USA). Corticoste-
rone was measured with a 125I radioimmunoassay. 
Statistical analysis. 
The statistical significance of differences between groups 
was calculated by comparing each experimental group with its 
control group using the unpaired Student's t-test. 
RESULTS. 
Effects of corticosterone administration. 
Treatment of rats with increasing amounts of corticosterone led 
to a progressive reduction of the acetone-ether powder LPL 
activity in animals fasted overnight (Table I). The decrease in 
activity (-43 %) was statistically significant at the highest 
dose of corticosterone administered (10 mg/rat per day). The 
decrease in heparin-elutable LPL activity followed a similar 
pattern. In rats not fasted overnight 1 a decrease in the 
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heparin-elutable activity was apparent only at the highest dose 
of corticosterone (Table I). In both fasted and fed rats, cor-
ticosterone administration led to a dose dependent increase in 
plasma concentrations of insulin and corticosterone 
Table II. Effect of ACTH (1·24) and/or corticosterone on adipose tissue 
lipoprotein lipase activity (LPL) in rats fasted overnight. Values are 
means ± S.E.M. 
n 
Treatment 
Intact 
Saline (12) 
Corticosterone (11) 
Corticosterone + (12) 
ACTH (1·24) 
Adrenalectomized 
Saline ( 8) 
Corticosterone (14) 
Corticosterone + ( 8) 
ACTH (1·24) 
Fat pad weight 
(mg) 
877±12 
634± 10 
590± 11 
463± 12 
665±9 
609±9 
Acetone ether powder 
LPL (mu./g wet wt) 
91 ±6 
41 ±3* 
106±6-t? 
72±5 
45 ±4 
100±5*# 
* P < 0.01 compared with intact control (saline) group; -::. P< 0.001 compared with corticosterone-treated 
intact group; * P < 0.01 compared with adrenalectomized corticosterone-treated group; # P < 0.05 
compared with adrenalectomized control (saline) group (unpaired Student's Hest). 
Rats were adrenalectomized 10 days before starting treatment with ACTH (1-24) (5 i.u.) and/or corti-
costerone (1 0 mg). 
Acetone--ether powder LPL activity was measured in extracts from defatted epididymal fat pads. 
Effects of administration of corticosterone plus 
ACTH (l-24). 
We have shown previously that hypercorticism induced by admi-
nistration of ACTH (1-24> (Synacthen) leads to an increase in 
acetone-ether powder LPL activity of fasted rats (9). We there-
fore wondered whether, during hypercorticism, LPL activity is 
differentially affected in the presence or absence of ACTH (1-
24). Administration of ACTH (1-24> plus corticosterone to intact 
rats, was found to abolish completely the lowering effect on LPL 
of corticosterone alone (Table II). In adrenalectomized rats 
acetone-ether powder LPL activity was lower than in intact rats. 
Corticosterone administration lowered further LPL activity per 
gram tissue. The total activity in the fat pads was not affected 
because of a corticosterone-induced rise in the fat pad weight. 
Concomitant administration of ACTH (1-24) and corticosterone led 
to increase in LPL activity above basal values. 
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DISCUSSION. 
Several hormones influence the activity of LPL with insulin and 
glucocorticoids seeming to be especially important. The exact 
role of glucocorticoids however is not clear. Opposite effects 
of corticosteroids on LPL activity have been reported. We have 
described the effects of hypercorticism, induced by the admini-
stration of ACTH (1-24>, on LPL activity (9). During this type 
of hypercorticism LPL activity, extractable from a defatted 
tissue preparation, which presumably represents the total LPL 
activity in the tissue, was enhanced if the rats were fasted 
overnight. In normally fed rats however, the activity was not 
further increased. The functional part of the enzyme, releasable 
from the tissue by heparin was not affected. This indicated that 
situations can exist in which only part of the total LPL acti-
vity in the tissue is hormonally affected. The present study 
shows that induction of hypercorticism by the administration of 
corticosterone leads to a decrease in the total, as well as in 
the heparin-releasable LPL activity in the epididymal adipose 
tissue, an effect which was found in normally fed and in those 
fasted overnight. These effects are opposite to those found 
after induction of hypercorticism by ACTH (1-24) administration. 
This apparent discrepancy was not due to a different level of 
corticosterone or insulin in the plasma, as both hormones 
reached comparable levels in both types of hypercorticism 
(cf.9). We therefore studied whether a combination of a higher 
concentration of corticosterone plus ACTH (1-24) or ACTH <1-24) 
alone 1 stimulated LPL activity differentially. The latter 
possibility appears to be unlikely as, after adrenalectomy, when 
endogenous ACTH levels are high, LPL activity is low. Moreover 
we have shown previously that treatment of adrenalectomized rats 
with ACTH (1-24) does not affect LPL activity (9). Simultaneous 
administration of ACTH (1-24) and corticosterone completely 
abolished the lowering effect of LPL activity by corticosterone 
in intact rats. In adrenalectomized rats LPL activity after 
administration of ACTH (1-24) plus corticosterone reached values 
even higher than those in adrenalectomized rats not treated with 
any hormone. The experiments with the adrenalectomized rats also 
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indicate that no other hormone is involved in the stimulatory 
effect of ACTH (1-24) on LPL. 
Based on these results, we postulate a direct stimulating effect 
of ACTH on the activity of LPL in the adipocyte of the rat. The 
inhibition of LPL during corticosterone administration may be 
due to suppression of endogenous ACTH secretion. Stimulation of 
LPL by ACTH (1-24> was seen only in the presence of cortico-
sterone (endogenous or exogenous). Therefore, both corticoste-
rone and ACTH appear to be necessary for the regulation of adi-
pose tissue LPL. 
In conclusion, in addition to insulin and glucocorticoids, ACTH 
seems to regulate LPL activity in adipose tissue of the rat. 
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CHAPTER VI 
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SUMMARY 
The effects of a-1-adrenergic receptor inhibition with doxazo-
sin, and ~-blockade with propranolol on tissue lipoprotein lipa-
ses and plasma lipids were studied in rats.In rats fed a nor-
mal lab chow, doxazosin increased heart lipoprotein lipase (LPL) 
activity (+ 14%), while propranolol had the opposite effect 
(-20%). These effects were not statistically significant when 
compared with nontreated controls,although the difference 
between the doxazosin and propranolol groups was significant (p 
< 0. OS) • There were no significant. effects on adipose tissue LPL 
activity or hepatic lipase (HL) activity.In rats fed a choles-
terol-enriched diet there were similar but smaller effects on 
heartLPL activity (+5% and -12% respectively). In these rats a-
1-inhibition also tended to increase adipose tissue LPL (+14%) 
and HL (+13%), while ~-blockade had an opposite effect <-20% and 
-9% respectively). The lipase activities were significantly dif-
ferent between the treatment groups in liver and heart but not 
in the adipose tissue. Doxazosin and propranolol did not affect 
plasma triglyceride or total cholesterol, but high-density lipo-
protein cholesterol was increased during a-1-blockade (+24%). 
INTRODUCTION 
Anti-hypertensive treatment with a- or ~-blockers produces dis-
parate effects on plasma lipid and lipoprotein levels (1). 
Although the results from different studies are variable, the 
emerging general picture is that a-1-adrenergic receptor inhi-
bition (a-1-inhibition) leads a more favorable lipid profile 
than ~-blockade. Plasma triglycerides are decreased, while high 
density lipoprotein (HDL) cholesterol is increased. The 
mechanisms that lead to these effects are at present unknown. 
Two lipases located in the vascular endothelium, LPL in extra-
hepatic tissues, and HL in the liver, play a key role in the 
metabolism of plasma triglycerides and HDL <2-4). Therefore 
changes in the activity of these enzymes could lead to the vari-
ations in plasma lipid concentration that occur during a- and 
~-blockade. Little is known about the adrenergic control of 
lipase activity although the effects of adrenergic stimuli have 
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been described for rat heart and adipose tissue LPL (5,6> and 
for rat HL (7). 
In a number of recent human studies, LPL activity in postheparin 
plasma was higher after a-1-inhibition than after S-blockade 
(8-10). In humans, the mechanisms of drug-induced changes in 
metabolism are difficult to assess. Moreover, beneficial or 
adverse effects of changes in plasma lipoproteins may become 
overt only after many years. Therefore we established the ef-
fects of a long-acting a-1-inhibitor, doxazosin, and of 
S-blockade with propranolol on lipoprotein lipases and plasma 
lipids in rats under different feeding conditions. 
MATERIALS AND METHODS 
Animals 
Rats (males from the Wistar strain,Hannover,F.R.G., 250-300 g) 
were housed under controlled conditions, (temp. 20°-23oC ,lights 
on between 08.00 and 19.00 h) and had free access to food and 
water, unless noted otherwise. 
Treatment procedures 
The food consisted of normal lab chow on its own or supplemented 
with 2% cholesterol (Hope's Farms, Woerden, The Netherlands). 
Drugs were added to the drinking water. Doxazosin (donated by 
Pfizer Central Research, Sandwich, U.K.) was dissolved in 0.4 M 
lactic acid (100 mg/ml) before being added to tap water <final 
concentration 100 mg/1) (7). Propranolol was dissolved in tap 
water at a concentration of 37.5 mg/1 and lactic acid was added 
later. The concentration of lactic acid in the drinking water of 
treatment groups and controls was in the same concentration 
(10-4M). The average water consumption was 40 ml/rat/day, there-
fore the rats received average daily doses of 4 mg of doxazosin 
or 1.5 mg of propranolol. This dose of propranolol has been 
shown to produce effective S-blockade in rats during intravenous 
administration (11). The dose of prazosin used has been reported 
to affect lipid parameters in rats (7). Drinking water was re-
newed every other day. Cholesterol was given for 3 weeks, and 
drugs and lactic acid were added to the drinking water over the 
last 7 days. 
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Biochemical methods 
The rats were killed by decapitation. Blood was collected in 
ice-cooled tubes, the liver was removed and a portion quickly 
frozen in liquid nitrogen. The heart was placed in ice-cold 0.9% 
NaCl pH 7. 2 and homogenized. Homogenates were diluted with a 
buffer containing heparin and sodium dodecyl sulphate (12), 
and LPL activity was determined within 1 h. Epididymal fat pads 
were immediately de1ipidated with acetone and diethylether 
(13). The defatted tissues were stored at -2o·c and assayed for 
LPL activity within 1 day. LPL activity was measured using a 
glycerol-stabilized tri-[3Hloleoyl glycerol emulsion as describ-
ed by Nilson-Ehle and Schotz (13). HL activity was measured in 
liver homogenates within 1 day using a gum acacia stabilized 
tri-[3H]oleoyl glycerol emulsion in the presence of 1 M NaCl 
(14). Triglyceride and cholesterol concentrations were determin-
ed enzymatically (Testkit combinations, Boehringer Mannheim, 
F.R.G.). HDL in pooled sera from five rats was separated from 
othe+ lipoproteins by ultracentrifugation (15). 
Statistics: The statistical significance of differences between 
groups was determined using the unpaired Student's t-test. 
RESULTS 
Effect of doxazosin and propranolol on lipoprotein lipase in rat 
heart and adipose tissue 
Lipoprotein lipase activity in rat heart and adipose tissue, and 
hepatic lipase activity in the liver was determined in rats 
treated with doxazosin or propranolol <Fig.1) and in age- and 
weight-matched controls that were not treated with either drug. 
In doxazosin-treated animals, heart LPL activity was higher than 
in the controls; in the propranolol-treated animals this acti-
vity was lower, but the effects were not statistically signifi-
cant. However, heart LPL activity was significantly higher with 
doxazosin than with propranolol. Adipose tissue LPL and HL acti-
vity were unaffected by either drug. When the results were ex-
pressed on a tissue wet weight basis, heart LPL activity was 
higher with doxazosin than with propranolol (719 ± 121 mU/g vs 
527 ± 115 mU/g). 
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FIG.1. 
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FIG. 1. Percentage change in heart and adipose tissue lipoprotein lipase and hepatic lipase acitivityduring 
treatment with doxazosin {Dox) and propranolol {Prop) in rats fed a normal lab chow. Mean ± SEM lipase 
activities per heart, left fat pad or liver are expressed as a percentage of a mean control value {heart 
lipoprotein lipase 478 mU, n = 5; adipose tissue lipoprotein lipase 215 mU, n = 11; hepatic lipase 4115 mU, 
n = 15). The percentage differences from controls {1 00%) are given. The significance of the between-groups 
differences are given {Student's t-test). 
FIG. 2. Percentage change in heart and adipose tissue lipoprotein lipase and hepatic lipase activity in 
cholesterol-fed rats during treatment with doxazosin (Dox) and propranolol (Prop). Results are expressed as 
in Fig. 1. Control values were: heart lipoprotein lipase 899 mU, n = 5; adipose tissue lipoprotein lipase 180 
mU, n = 5; hepatic lipase 3120 mU, n = 15. 
Effect of adrenergic blockade on lipoprotein lipase and hepatic 
lipase in cholesterol-fed rats. 
In the hearts of rats fed a cholesterol-enriched diet the LPL 
activity was higher than in the hearts of rats fed a normal lab 
diet (683 ± 112 mU/heart vs 899 ±95 mU/heart, means ± SD, n = 
10). HL activity was lower in the cholesterol-fed rats than in 
the control-fed rats (4115 ± 53, n =10 vs. 3119 ± 444, n = 15 
mU/liver). LPL activity in adipose tissue was similar in rats on 
both diets. 
In cholesterol-fed rats, the effects of a-1- and ~-blockade on 
heart LPL were similar to those in control fed rats, with a 
relative increase during doxazosin treatment when compared with 
propranolol treatment (Fig.2). In adipose tissue the same trends 
were observed although the changes were statistically not signi-
ficant. 
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Table I. Effects of doxazosin and propranolol on plasma cholesterol and 
triglyceride.s 
Plasma concentration (mM) 
Drug TG TC HDL 
cholesterol 
None (11) 0.46±0.16 1.83±0.59 0.49 ±O.o7a 
Doxazosi n ( 11) 0.68±0.25 1.85±0.60 0.61 ±0.03b 
Propranolol (11) 0.47 ±0.20 1.74±0.46 0.48 ±O.o3a 
Mean plasma values± SO after the treatment period, number of rats given in brackets. 
TG. =plasma triglycerides, TC =total cholesterol. 
a versus b, p < 0.05. 
HL increased in the doxazosin group and increased in the propra-
nolol group, although these changes were not significant. How-
ever, the difference between both treatment groups was statisti-
cally significant Cp < 0.05). 
Plasma lipid values in cholesterol-fed rats during adrenergic 
blockade 
Doxazosin and propranolol did not affect total plasma choles-
terol or triglyceride content in cholesterol-fed rats (Table I). 
HDL-cholesterol increased significantly in the doxazosin group 
when compared with controls and propranolol treated rats. HDL-
cholesterol was unaffected in the pro2ranolol group. 
Table 11. Insulin and thyroid hormones in cholesterol-fed rats during a-
and {3 ·blockade 
Treatment Insulin T3 (nM) T4 (nM) 
(mU/ml) 
None (10) 11.5±5.3 1.10 ± 0.20 44±10 
Doxazosin (1 0) 15.2±8.6a 1.21 ±0.17C 43± 8 
Propranolol (1 0) 8.5 ± 2.7b 0.96±0.22d 45 ± 9 
Mean plasma values± SO after the treatment period a versus b and c versus d, P < 0.05. 
Insulin and thyroid hormone levels 
As the secretion of several hormones may be affected by adrener-
gic stimuli, plasma levels of insulin and thyroid hormones were 
determined (Table II). Doxazosin and propranolol did not sig-
nificantly affect these hormone levels when rats treated with 
these drugs were compared with controls. However, insulin and T3 
in the doxazosin group were significantly higher than in the 
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propranolol group. 
DISCUSSION 
This study demonstrates that short-term treatment of rats with 
the long-acting a-1-adrenergic inhibitor doxazosin leads to a 
significantly higher heart muscle LPL activity than short-term 
treatment with propranolol. In cholesterol-fed rats HL activity 
and HDL-cholesterol were relatively enhanced during the a-1-
inhibition. Adipose tissue LPL was not significantly affected. 
In human studies a relative increase in post-heparin LPL acti-
vity has been described during a-1-blockade <8-10). As the post-
heparin lipase is derived from several tissues, the origin of an 
enhanced activity in postheparin LPL activity is not clear, but 
in view of our present studies it is tempting to suggest that in 
humans also, LPL, mainly <heart) muscle, is affected by adrener-
gic blockers. In patients on hemodialysis, ~-blockade was found 
to lower HL activity (8), while in another study no effects were 
observed (10). In rats, a differential effect of a- and~­
blockade on HL was found only when they were fed a cholesterol-
rich diet. The reason for these discrepancies is unclear but may 
relate to changing adrenergic activity under differing condi-
tions. However, it is generally true that the effec.ts of a- and 
~-blockade on lipoprotein lipases in rats and humans are simi-
lar. In the present study prazosin was applied at a dose compa-
rable to that used in humans. However, the propranolol dose was 
less than that used in humans; whether a higher dose would have 
led to exaggerated lipid effects was not studied. 
Dall'Agglio et al. (16), described an increase in HDL-choles-
terol and a decrease in plasma triglycerides during a-blockade 
in rats fed normally. They suggested that the decrease in tri-
glycerides may result from an impaired VLDL secretion. In view 
of the present findings it seems likely that an increased cata-
bolism of VLDL under the influence of elevated LPL activity 
plays a role. This mechanism would also explain the increase in 
HDLcholesterol. Of special interest are the effects of a- and 
~-blockade in the cholesterol-fed rats. It was previously found 
that norepinephrine treatment of cholesterol-fed (but not of 
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normal lab chow-fed) rats leads to hypercholesterolemia and to a 
decrease in HDL-cholesterol and HL activity (H. Jansen, un-
published results). 
The question arises, does a- or ~-blockade would reverse these 
effects? As can be seen from Fig.2, the decrease of hepatic 
lipase activity during cholesterol feeding is partly abolished 
by doxazosin treatment, while in propranolol-treated rats the 
lipase activity was further lowered. The difference in HL acti-
vity between both groups was significant (p < 0.05). As HL may 
play a role in uptake of HDL-cholesterol by the liver (4,17,18), 
this may be facilitated during a-1-inhibition in contrast to 
during ~-blockade. 
In the cholesterol-fed rats this did not reduce HDL-cholesterol 
concentration; instead HDL-cholesterol increased during a-1-
inhibition, which indicates that other mechanisms are operative. 
One such mechanism may consist, at least partly, of an enhanced 
rate of triglyceride catabolism under the influence of an ele-
vated LPL activity. 
These data taken together suggest that in normally fed and 
cholesterol-fed rats, a-1-inhibition with doxazosin produces 
changes in plasma lipids and lipoprotein lipases that can be 
interpreted as beneficial in the sense that they may contribute 
to a more efficient cholesterol transport to the liver (18), 
which is in contrast to the effects of the ~-blocker proprano-
lol. 
This view requires experimental confirmation. It is not known 
whether the effects obtained are exerted directly via adrenergic 
receptors or via other hormones. In the cholesterol-fed rats 
plasma insulin and T3 levels were slightly affected. As these 
hormones may also affect lipase activities, the influence of the 
adrenergic blockers may be indirect. It is therefore important 
to determine the levels of these hormones during intervention 
with adrenergic blockers. 
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SUMMARY. 
Male patients (52) with mild hypertension who had undergone 
coronary bypass grafting (CABGl were randomly allocated to 
propranolol or prazosin treatment. Plasma lipid parameters were 
measured on 3 occasions: at the start of the treatment 6 weeks 
postoperatively <visit 1), 3 months (visit 2) and 6-9 months 
(visit 3) later. The effects of both drugs on lipid parameters 
were compared using analysis of covariance. During the first 
period (visit 1 to visit 2) prazosin treatment, in comparison to 
propranolol, led to a lower plasma triglyceride (mean treatment 
difference (m.t.d.) -25%) and a higher HDL-cholesterol/total 
cholesterol ratio (m.t.d. +14%). During prolonged treatment (6-9 
months) prazosin resulted in, beside a consistant lower tri-
glyceride level (m.t.d. -20%) and a higher HDL-cholesterol/total 
cholesterol ratio (m.t.d. +14%), a significantly higher HDL-
cholesterol level (m.t.d. +12%) and lipoprotein lipase activity 
(m.t.d. +20%) than propranolol. Propranolol and prazosin did not 
differentially affect hepatic lipase activity. These results in-
dicate that effects of adrenoceptor blockers on lipoprotein 
lipase activity may be part of the mechanisms leading to 
differential influences of alpha- and beta-blockers on plasma 
lipid levels. 
INTRODUCTION. 
Hypertension has been recognized as a major risk factor for the 
development of premature atherosclerosis leading to coronary 
heart disease. However antihypertensive treatment with beta-
blockers fails to substantially prevent the occurrence of coro-
nary heart disease. The explanation may be that this treatment 
also affects lipid metabolism. The changes in plasma lipid 
levels are such that the possible beneficial effect of the 
lowering of the blood pressure is counteracted by adverse 
effects on plasma lipid levels, especially on cholesterol and 
triglycerides. In a number of studies it has been shown that 
beta-blockade can lead to an increase in plasma low-density 
lipoprotein (LDL) cholesterol and triglycerides and a decrease 
in high-density-lipoprotein (HDL) cholesterol (1-4). 
101 
Alpha-adrenoceptor blockade has been reported to have an 
opposite effect (1-4). Little is known about the mechanisms 
which lead to the changes in lipoprotein levels during adreno-
ceptor blockade. Two endothelially located lipases, lipoprotein 
lipase CLPL> in extrahepatic tissues and hepatic lipase (HL) in 
the liver play an important role in lipoprotein metabolism and 
seem to be major determinants of plasma triglyceride and HDL 
levels (5). To study the possible involvement of these enzymes 
in the lipoprotein changes during treatment of hypertension with 
alpha- or beta-blockers we determined the activity of the 
enzymes in patients who had undergone coronary bypass grafting 
and were treated with either the beta-blocker, propranolol, or 
the alpha-1-specific blocker, prazosin. 
PATIENTS AND METHODS. 
Fifty two male patients entered the study. They had undergone a 
first isolated coronary artery bypass grafting CCABG) and had 
moderate hypertension (systolic 150-190 mmHg, diastolic 90-120 
mmHg> and were not in need of beta-blocking agents. Exclusion 
criteria were severe heart failure, valvular heart disease, 
recent (< 3 months) myocardial infarction, slow heart rate (< 50 
b.p.m.), pulmonary disease for which medication had to be taken, 
anaemia (Hb < 6.5 mM/1), diabetes mellitus, hypothyroidism and 
secondary hyperlipidemia. 
Study design. 
After informed consent was obtained, randomization was carried 
out before CABG. The assignment to a treatment group was deter-
mined by drawing an envelope containing a note on the drug to be 
used. Six weeks after CABG the patients were seen at the out-
patient service of the Thoraxcenter of Rotterdam (visit 1). Dur-
ing this visit blood samples were taken to obtain base-line 
information on lipid profile, biochemistry and enzymes and the 
hypertension treatment started. Visit 2 was 3 months after visit 
1 and visit 3, the end of the study period, 6-9 months after 
visit 1. 
Drug administration. 
Prazosin was given twice daily, starting with 2 mg per day. 
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Propranolol was taken 3 times a day, start~ng with 60 mg per 
day. The dosage of the drugs was adjusted dependent on the 
effect on the bloodpressure until a level equal to or below 90 
mmHg diastolic and 150 mmHg systolic was reached. Prazosin was 
prescribed with a mean dose of 2.8 mg per day, range 1.5-15 mg, 
Propranolol at 110 mg per day, range 20-160 mg. 
Chemical methods. 
Plasma triglycerides (6), and total cholesterol (7) were 
measured with standard enzymatic laboratory methods. HDL 
cholesterol was determined after precipitation of other lipo-
proteins with heparin and manganese2+ and with phosphotungstic 
acid plus magne~ium2+ (8). HDL subtractions were separated as 
described by Gidez et al. (9). The fraction that is precipitated 
with dextran-sulphate is indicated as HDL2 and the fraction that 
remains in solution as HDL3. LDL cholesterol was calculated with 
the Friedewald formula (10). 
LPL and HL activities in postheparin blood plasma were measured 
with the immunochemical method described by Huttunen et al. 
(11). The blood samples were withdrawn 20 min after the intra-
venous administration of 50 IU heparin/kg bodyweight. Intra-
assay variation in LPL was 2.6% and inter-assay variation 4.4%. 
Intra-assay variation in HL 3.5% and inter-assay variation 6.8%. 
Statistical Methods .. 
All results are expressed as means ± 1 s.d. Lipid parameters at 
different time points were compared with the values at visit 1 
using the paired t-test (12). To compare the influence of prazo-
sin and propranolol treatment on the lipid profile, analysis of 
covariance (13) was performed to correct for a possible incom-
parability of the base-line data. Data concerning the lipid pro-
file of 24 patients treated with prazosin and 26 patients 
treated with propranolol at visit 1 and visit 2 were compared. 
The same comparison was made for visit 1 and visit 3 with 22 
patients on prazosin and 24 on propranolol. The mean treatment 
differences were adjusted for baseline incomparability. The 
analysis showed no evidence for inequality of slopes between the 
two treatment groups. 
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Table I 
Plasma lipid and lipoprotein Concentrations during Propranolol Treatment. 
Variable (mM) Visit 1 Visit 2 Visit3 
(n=26) {n=26) (n=24) 
Triglyceride 2.24± 1.10 2.04±0.87 2.18 ±0.82 
Total cholesterol 6.20 ± 1.33 6.92 ± 1.29* 6.90 ± 1.32* 
lDl-cholesterol 4.24±0.99 4.98±0.94* 4.87 ± 1.03* 
HDl-cholesterol 0.90±0.23 1.00±0.25* 1.03 ±0.25* 
HDl2-cholesterol 0.16 ±0.09 0.16 ±0.08 0.14±0.08 
HDl3-cholesterol 0.70±0.14 0.80 ±0.23* 0.83 ± 0.15*** 
Ratio HDl-C/TC 0.14 ± 0.03 0.14 ± 0.03 0.15 ±0.04 
• denotes a statistically significant difference from visit 1 with p < 0.05, ** p < 0.01 and 
*** p < 0.001. LDL-cholesterol =low density lipoprotein cholesterol, HDL-cholesterol, HDL-
C =high density lipoprotein cholesterol, TC =total plasma cholesterol. 
Table II 
Plasma lipid and lipoprotein Concentrations during Prazosin Treatment. 
Variable (mM) Visit 1 Visit2 Visit3 
(n=25) (n=24) (n=22) 
Triglyceride 2.25 ± 1.47 1.47 ± 0.68** 1.74± 1.04* 
Total cholesterol 5.85 ± 1.27 6.37 ± 1.00* 6.18 ± 1.03 
lDl-cholesterol 3.90 ± 1.12 4.52±0.88* 4.27±0.74 
HDl-cholesterol 0.92 ±0.21 1.09 ± 0.21 ** 1.13 ± 0.24** 
HDl2·cholesterol 0.17 ±0.09 0.18±0.13 0.20 ± 0.15 
HDls·cholesterol 0.74 ± 0.16 0.88 ± 0. 14*** 0.89±0.14*** 
Ratio HDl-C/TC 0.16 ±0.04 0.17 ±0.04 0.18 ± 0.04++ 
*denotes a statistical significant difference from visit 1 with p < 0.05, ** p < 0.01 and 
*** p < 0.001. LDL-cholesterol =low density lipoprotein cholesterol, HDL-cholesterol, HDL-
C =high density lipoprotein cholesterol, TC =total plasma cholesterol. 
RESULTS. 
Patient population follow-up. 
One of the patients admitted to the randomization procedure was 
excluded from the analysis because of protocol violations before 
the start of the study therapy. From the remaining 51 patients 
25 were placed in the prazosin and 26 in the propranolol group. 
The median age of the men receiving prazosin was 57 years, range 
41-69, and propranolol: 57 years, range 38-68. Three patients on 
prazosin discontinued trial medication prematurely. The reasons 
for discontinuation were: severe angina pectoris (2), dizziness 
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and palpitations (1). One patient's data on propranolol were 
incomplete due to an administrative error and one patient, 
participating in the propranolol group, deceased. Hence 22 
patients of the prazosin group and 24 patients of the propra-
nolol group completed the study. 
Plasma lipid values. 
In both treatment groups considerable changes in plasma lipid 
values in comparison to visit 1 had occurred at visit 2 and 
visit 3 (Tables I,II). In the propranolol group total choles-
terol, LDL cholesterol and HDL cholesterol levels were increased 
on both occasions (Table I). The elevation in HDL cholesterol 
was mainly in the HDL3 fraction. In the Prazosin group the total 
cholesterol and the LDL cholesterol concentrations were increas-
ed at visit 2, returning to basal values at visit 3 in compari-
son to visit 1. HDL cholesterol showed an increase at visit 2 
and 3, also mainly due to a higher level of HDL3 cholesterol. 
The ratio of HDL- cholesterol/total cholesterol was in the 
prazosin group significantly enhanced at visit 3. Another major 
effect in the prazosin group was a substantial decrease in the 
plasma triglyceride concentration at visits 2 and 3. 
While part of the changes may due to recovery from the post-
surgical situation probably present at visit 1 covariance 
analysis of the data was carried out to compare the specific 
effects of the treatment with either drug. Prazosin treatment 
resulted in a significantly lower plasma triglyceride concen-
tration than propranolol treatment at visit 2 and at visit 3. 
The m.t.d. are shown in Fig 1. There was no statistically 
significant difference between the treatment effects on HDL 
cholesterol levels at visit 2. At visit 3 the prazosin treatment 
was found to result in a higher HDL cholesterol concentration 
than the propranolol treatment (mean treatment difference = 0.11 
mM; 12% of the initial value, p < 0.05). If this fraction was 
determined after precipitation of the other lipoproteins with 
phosphotungstic acid and magnesium the trend was the same, but 
the treatment difference was not statistically significant 
(0.088 roM, p = 0.14). Prazosin treated men had an increased HDL 
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cholesterol/total cholesterol ratio at visit 2 and visit 3 
compared to the patients taking propranolol (m.t.d. on both 
occasions= 0.021; 14% of initial value, with p < 0.05). 
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The mean treatment difference in the values during Prazosin treatment minus the 
values during Propranolol treatment are given. At the bottom of the fig. the actual 
p values are shown. The open bars relate to the data at visit 2, the black bars relate 
to the data at visit 3. 
Lipase activities. 
At visit 2 the LPL activity in the prazosin group was higher 
than at visit 1 (Table III). At visit 3 the activity was less 
enhanced and the difference with visit 1 was no longer statisti-
cally significant. LPL activity did not change during the study 
period in the propranolol treated patients. 
Comparing the effect of treatment with prazosin with the 
treatment with propranolol using covariance analysis the 
prazosin treatment was found to lead to a higher LPL activity 
than propranolol treatment. The mean treatment difference at 
visit 2 and visit 3 about 20 % of the initial value <p = 0.05, 
Table III). HL activity tended to increase at visit 2 in all 
patients but this effect was only statistically significant 
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Table Ill. 
Postheparin Plasma Lipase Activities during Treatment with Prazosin or 
Propranolol. 
Enzyme 
(mUnits/ml) 
Lipoprotein Lipase 
Hepatic Lipase 
Visit 
1 
2 
3 
2 
3 
Prazosin Propranolol 
67±24 69± 28 
89±33* 75± 27 
78±27 64± 20 
281 ±106 251 ± 91 
295±98 301 ±110* 
263±65 268± 105 
• denotes a statistically significant difference from visit 1 with p < 0.05. 
in the propranolol group. At visit 3 neither in the propranolol 
nor in the prazosin group a substantial difference from visit 1 
in HL activity was found. Covariance analysis showed no diffe-
rential effect between treatment with either drug on HL activi-
ty. The mean treatment differences were less than 7% of the 
initial values. 
DISCUSSION. 
In this study the possible involvement of LPL and/or HL in the 
changes in plasma lipid levels provoked by adrenoceptor blockade 
was studied. Therefore the effects of prazosin and propranolol 
treatment on plasma lipids, lipoproteins and postheparin lipase 
activities were compared in mildly hypertensive patients who had 
undergone coronary artery bypass grafting. Two main conclusions 
could be drawn: prazosin treatment leads in comparison to 
propranolol to 1. a more favorable lipid profile (a lower plasma 
triglyceride, a higher HDL-cholesterol and a higher HDL-choles-
terol/total cholesterol ratio) and 2. a relatively higher LPL 
activity. Opposite changes in the concentration of HDL and 
plasma triglycerides may causally be related. During the degra-
dation of triglycerides in VLDLs or chylomicrons by LPL surface 
material is released from these lipoproteins and becomes as-
sociated with the HDL fraction <5,14). A rapid VLDL catabolism 
may therefore lead to a low plasma triglyceride and a high HDL 
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The data are presented in the same way as in Fig. 1. 
concentration. Plasma triglycerides were at the start of the 
study period (visit 1) higher (means around 2.25 mM) and HDL 
cholesterol lower (around 0.90 mM) than normally found. LPL was 
in the low-normal range (mean LPL patients around 68 mU/ml, 
normal 65-120 mU/ml. This picture, probably a postsurgical 
phenomenon, suggests a situation of impaired triglyceride 
catabolism at least partly due to the relatively low LPL 
activity. LPL activity was inversely correlated to the plasma 
triglyceride concentration (r = -0.30) 1 which illustrates the 
importance of this lipase activity as a de-terminant of the 
triglyceride level. The simultaneous decrease in plasma tri-
glyceride (-35%) and increase in HDL cholesterol (+ 16%) that 
occurred between visit 1 and 2 in the prazosin treated patients 
probably results from an enhanced degradation rate of VLDL 
triglyceride resulting from an increased LPL activity (+33%). 
During propranolol administration the changes in this period 
were much smaller (triglyceride -10%, HDL cholesterol +10%, LPL 
+9%) and only significant in HDL cholesterol. Since in the 
period between visit 1 and visit 2 presumably the effect of a 
recovery of the postsurgical to a normal situation also 
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influences the plasma lipid concentrations, the effects observed 
cannot completely be ascribed to the drug treatment. Therefore 
to compare the effects of both drugs analysis of covariance was 
carried out. From this analysis appeared that prazosin treatment 
leads to a statistically lower plasma triglyceride and a higher 
HDL cholesterol/total cholesterol value in comparison to propra-
nolol treatment. On the long-term (visit 3) the differences in 
these variables remained, while differences in other lipoprotein 
variables between prazosin treatment and propranolol treatment 
that were already apparent at visit 2 became statistically 
significant, notably: a higher HDL cholesterol level and a 
higher LPL activity during prazosin than during propranolol 
treatment. Why the effects on HDL cholesterol concentrations 
were more clear when the other lipoproteins were precipitated 
with heparin-manganese instead of phosphotungstic acid and 
magnesium is not clear. It seems to indicate that both methods 
are not completely comparable. As discussed above the opposite 
effect~ of alpha- and betablockade on plasma lipids may partly 
result from inverse effects of the blockers on LPL activity. It 
is clear however that not all changes in plasma lipoproteins can 
be ascribed to alterations in the activity of this enzyme. For 
example, LPL activity in the prazosin group was not signifi-
cantly different from visit 1 and still triglycerides were 
lowered and HDL cholesterol enhanced. HL seems not to be 
involved as this enzyme showed similar activity in both groups. 
An effect on plasma triglyceride clearing during adrenergic 
blockade has been suggested before. Ferrara et al. (15) found an 
increase in postheparin lipolytic activity during short-term 
treatment with prazosin. LPL and HL were however not separately 
measured in this study. Harter et al. (16) found, very small, 
inverse changes in LPL (+2.5% and -2.5 %, resp.) during alpha-
and beta blockade in patients on hemodialysis, while Day et al. 
(17) demonstrated a decrease in the catabolic rate of plasma 
triglyceride following beta-blockade. In this latter study 
plasma triglycerides increased during beta-blockade and the 
authors suggested a lowering in LPL activity. Lithell and 
coworkers (18) found no effect of prazosin on LPL in biopsies of 
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muscle and adipose tissue. However, in their study women who had 
initially a low plasma triglyceride and a relatively high HDL 
level were studied. This suggests that in contrast to the 
initial situation in our study VLDL catabolism was already 
rapid and LPL activity high. In this case LPL may not be further 
stimulated by alpha-blockade, but, as in the study by Day et al. 
(17), may indeed be lowered by beta-blockade. While the dif-
ferential effect of alpha- and beta blockade on LPL at least 
partly explains the inverse alterations in HDL and plasma 
triglycerides other mechanisms may be operative too. In conclu-
sion: antihypertensive treatment with the alpha1-specific 
blocker, prazosin leads to a more favorable lipid profile than 
the beta-blocking agent propranolol; an important factor in the 
generation of this favorable lipid profile may be a higher LPL 
activity in the prazosin treated patients. 
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CHAPTER VIII 
GENERAL DISCUSSION 
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GENERAL DISCUSSION. 
Lipoprotein lipase (LPL; EC 3.1.1.34) activity in adipose tissue 
was studied in vitro, in the selectively perfused epididymal 
fatpad of the rat, and in post-heparin plasma of humans. 
The synthesis of LPL in the adipocyte is under control of 
several hormones, of which insulin is probably the most impor-
tant. The enzyme is transported via an unknown mechanism, but 
probably is a glycosylation step necessary, while the intra-
cellular microtubular system is involved. The enzyme is 
functional at the endothelial site of the capillary wall, bound 
to heparan-sulphate, from which binding sites it can be released 
by heparin. 
Fig. 1: A schematical representation of the nieasarable LPL pools in adipose tissue. 
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Some groups have found an inhibitory effect of several weeks 
administration of glucocorticoids on LPL activity, whileothers 
reported a stimulating effect of one dose. We made rats hyper-
corticistic by giving them a daily subcutaneous injection of 
Synacthen, a synthetic corticotrophin analogue for 3 days or 
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longer (Chapter III). This regimen leads to an important eleva-
tion of the corticosterone production and plasma corticosterone 
levels in fasted and fed animals (610 ± 137 ng/ml, controls 258 
± 120 ng/ml). While total body weight is decreasing the weight 
of the epididymal fat pad of the hypercorticistic animal is 
preserved. This hypercorticism leads also to an increase of 
plasma insulin levels. From 7.8 ± 4.7 ~U/ml in fasted controls 
to 20.6 ± 8.4 ~U/ml in fasted hypercorticistic animals. These 
last levels are the same as the insulin levels in fed controls 
(25.0 ± 3.7 ~U/ml). Longterm treatment (20 days) does not raise 
insulin levels further in fasted groups, but do so in the fed 
treated groups <45.0 ± 7.8 ~U/ml). 
LPL activity, measured in an extract of an acetone-ether powder 
of the epididymal fat pad is stimulated by feeding. Adrenal-
ectomy lowered the LPL-activity in overnight fasted as well as 
in fed animals. Synacthen treatment induced an increase of the 
LPL-activity in intact fasted animals (from 84 ± 15 to 140 ± 25 
mU/gwwl, that is to levels found in the untreated fed group. In 
fed animals no increase in LPL-activity by Synacthen is observ-
ed. 
This is in contrast to the data of Lawson et al. (1) who found a 
decrease in adipose tissue LPL activity. However, he used a much 
lower dose of ACTH and studied the enzyme only after feeding. 
Moreover he did not find the effect throughout the year, but 
only in the winter. We did not observe any in vitro effect of 
ACTH on LPL after feeding and the stimulating effect of ACTH 
after overnight fasting was observed the whole year through. 
The fact that Chernick et al. (2) did not find an effect of ACTH 
on LPL activity in 3T3-Ll adipocytes, is in line which our ob-
servation that ACTH needs corticosterone to express the effect 
on adipose tissue LPL activity: Synacthen treatment did not 
raise the LPL-activity in fasted nor fed adrenalectomized 
animals. The heparin-elutable LPL-activity, which is to be 
believed to represent the physiologically active LPL pool of the 
epididymal fat pad in vitro is an order of magnitude higher 
after feeding the rat, (29 ± 7 and 444 ± 102 mU/gww, respective-
ly). The differences in milli-units enzyme activity found with 
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the acetone-ether powder and heparin-elutable method may be 
explained by the fact that heparin stabilizes LPL. It is also 
possible that a fraction of the LPL-activity is inactivated by 
the procedure in making an acetone-ether powder. Synacthen does 
not have any effect on the heparin-elutable LPL-activity in 
fasted, nor fed animals in vitro. 
Table I. Scheme of Intracellular Regulation of lipoprotein lipase Synthesis. 
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The induction of hypercorticism by the administration of corti-
costerone instead of ACTH leads to a decrease in the LPL acti-
vity from an extract of an acetone-ether powder as well as in 
the heparin-elutable epididymal adipose tissue LPL activity in 
vitro (Chapter V). 
This effect was found in normally fed and in overnight fasted 
animals. This is in line with data reported by de Gasquet et al. 
(3), Krotkiewski et al. (4), Bagdade et al. (5) and Cigiloni & 
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Smith (6). Although in another study De Gasquet et al. (7) found 
an increase in adipose tissue LPL activity several hours after 
an intraperitoneally injection of dexamethasone or corticoste-
rone in fed and fasted animals. Ashby et al. (8) found in vitro 
a stimulation of LPL activity after administration of glucocor-
ticoids. This is not necessarily in contrast to our findings, 
since he used a much higher concentration of insulin in the 
incubation medium. Moreover he found the strongest effects with 
synthetic glucocorticoids and not with corticosterone. The 
effects of corticosterone that we observed are opposite to those 
found after induction of hypercorticism by corticotrophin ad-
ministration. This apparent discrepancy was not due to a diffe-
rent level of corticosterone or insulin in the plasma as both 
hormones reached comparable levels in both types of hypercor-
ticism (Chapter III). Therefore we investigated the possibility 
whether a combination of a high corticosterone level plus corti-
cotrophin or corticotrophin alone may stimulate LPL. The last 
possibility appears to be unlikely as after adrenalectomy, when 
endogenous corticotrophin levels are high, LPL activity is low. 
Moreover we showed also that Synacthen treatment of adrenal-
ectomized rats does not affect LPL activity <Chapter III). When 
corticotrophin and corticosterone were simultaneously admini-
stered to intact rats the lowering of LPL. activity by cortico-
sterone was completely abolished. In adrenalectomized rats 
treated with corticotrophin plus corticosterone the LPL activity 
reached values significantly higher than in the adrenalectomized 
rats not treated with either hormone. The experiments with the 
adrenalectomized rats also indicate that in the stimulatory 
effect of corticotrophin on LPL probably no other adrenal hor-
mone is involved than corticosterone. Based on these results it 
is clear that corticotrophin has a direct stimulating effect on 
the activity of LPL in the adipocyte of the rat. The inhibition 
of LPL during corticosterone administration may be due to sup-
pression of the endogenous corticotrophin secretion. Stimulation 
of LPL by corticotrophin was only seen in the presence of (endo-
genous or exogenous) corticosterone. Therefore corticosterone 
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and corticotrophin appear to be both necessary for the regula-
tion of adipose tissue LPL. 
To study the physiological meaning for the adipose tissue of the 
effects of Synacthen on LPL activity and on the balance of in-
and efflux of fatty acids, the epididymal fat pad was selecti-
vely perfused <Chapter II). We applied some modifications to the 
perfusion technique, of the epididymal fat pad as described by 
Ho and Meng (9). We aimed at preventing swelling of the tissue 
and at maintaining it in a good condition during the procedure. 
Judged by the ATP content and energy charge of the adipose 
tissue before and after perfusion, the tissue could be kept in 
a metabolically healthy state for at least 150 minutes. This was 
accomplished using a perfusion rate of maximally 100 ~l medium 
per min <in vivo the flow rate is 70 ~1/g/minl and a medium 
containing albumin, glucose, insulin, amino acids and red blood 
cells as oxygen carrier. During all experiments we observed a 
spontaneous LPL-release into the perfusion medium. This has also 
been reported by Scow et al. (10), but not by Fielding et al. 
(11) . The activity released into the medium by adipose tissue 
from fasted animals was about 1 o/oo per minute of the total 
LPL activity in the tissue. In the fed state the absolute spon-
taneous release of LPL activity was 4 - 5 times higher, but as a 
percentage of the LPL activity present in the fat pad not diffe-
rent from that in fasted animals. Upon addition of heparin to 
the perfusion medium the release of the enzyme rose to 20 - 25 
times over the basal value. 
As described above the enzyme activity released by heparin elu-
tion in vitro was from the adipose tissue of fed rats 10 or more 
times higher than from the fasted animals, while a factor 2 to 4 
was found in acetone-ether powder extracts of the epididymal fat 
pads of the fed and fasted animals <Chapter III). In the perfu-
sed epididymal fat pad LPL activity was measured in the post-
perfusion medium (during perfusion heparin was added to the 
medium) and we found that the heparin-releasable LPL was 3-5 
times higher in the fed than in the fasted animals. Therefore, 
with the in vitro heparin elution method, to determine LPL acti-
vity, in the adipose tissue from the fed animals not only the 
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enzyme in the vascular compartment appears to be measured. How-
ever, LPL is a labile enzyme and its activity rapidly decreases 
at 37°C. Although the sum of the LPL activity released from the 
endothelium and the remaining LPL activity in the fat pad after 
the perfusion procedure (acetone-ether method) was equal to the 
activity extracted from the non-perfused fat pad <acetone-ether 
method), this does not exclude the possibility of an underes-
timation of LPL activity during the heparin perfusion. 
The heparin-releasable pool of LPL activity measured by perfu-
sion of the epididymal fat pad is 10%-20% of the total pool, in 
the fasted as well as in the fed state, which means that not 
only the synthesis, but also the transport of LPL to the vascu-
lar wall is enhanced. A strong correlation was found between the 
rate of chylomicron-TG hydrolysis and the total amount of hepa-
rin-releasable LPL in the perfusion medium (r = 0.94 in fasted 
and r = 0.96 in fed animals). This once more establishes the 
conclusion that the LPL activity in the vascular compartment is 
the physiologically active fraction. 
We found that the LPL activity measured in vitro is influenced 
by the FA-concentration: the enzyme activity is low if fatty 
acid-free albumin was used and increases to a maximum when the 
FA-load was raised to a FA/albumin ratio of 5 1. Albumin 
saturated with FA in the medium inhibited the LPL activity. In 
the perfusion model of the fat pad when fatty acid free albumin 
was used in the medium also no hydrolysis of chylomicrons could 
be detected. Using albumin with varying amounts of FA complexed 
to it, hydrolysis of chylomicron-TG and uptake of the FA releas-
ed occurred. The rate of these processes did not change with 
different FA/albumin ratios. So in situ the relationship between 
FA-albumin and LPL activity appears less important than it seems 
to be in vitro. One of the possible explanations for this diffe-
rence could be that under the conditions of the perfusion the 
adipose tissue by itself is a FA acceptor too. As to the 
influence of flow rate Scow et al. (10) described a relationship 
between the FFA released from the fat pad with that variable, 
but he did not report on an influence of flow rate on chylomi-
cron hydrolysis. We found a percentual increase of the 
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chylomicron hydrolysis if the flow rate was lowered, but the 
uptake of liberated fatty acids did not increase. 
In fact not the hydrolysis of TG by LPL, but the uptake of FA by 
the adipose tissue appears to be the limiting factor. 
The hydrolysis of chylomicrons and VLDL is low in the fasted 
state. In fed animals the hydrolysis of chylomicron-TG is 
higher, but VLDL-TG hydrolysis remains unchanged. These diffe-
rences were also found for the uptake of the liberated TG-FA. 
This is in line with the general idea that chylomicron-TG is 
preferentially taken up by adipose tissue and VLDL-TG by muscle 
tissue. However it should be kept in mind that in contrast to 
the chylomicrons used VLDL isolated from plasma has already been 
in contact with LPL. Therefore, the particles isolated may be 
regarded as remnant particles from VLDL and a less good sub-
strate for LPL. It is difficult to compare our results with data 
derived from in vivo studies on the uptake of liberated FA from 
chylomicron-TG by adipose tissue, since the liver is removing 
most pf it after an intravenous injection. However, the uptake 
of chylomicron-TG-FA in perfused adipose tissue in our hands is 
comparable to that calculated by Scow et al. (10) from their 
experiments with perfused parametrial fat. 
The uptake of liberated FA is correlated with the chylomicron-TG 
concentration in the medium at least up to 4 mM TG; higher con-
centrations were not used. 
In the hypercorticistic rats <by Synacthen treatment), the hepa-
rin-releasable LPL activity in the effluent of the perfused 
epididymal fat pad rose from 3 ± 1 mU to 12 ± 8 mU (in a sixty 
minutes lasting perfusion; mean ± SD) in fasted animals. How-
ever, in fed animals the heparin-releasable LPL-pool has a much 
higher activity than in the fasted treated animals (36 ± 20 
respectively 12 ± 8 mU), and Synacthen treatment did not further 
increase this pool in the fed animals (30 ± 13 mU). This is in 
contrast to the lack of influence of Synacthen treatment on the 
heparin-elutable LPL activity in in vitro experiments with the 
epididymal fatpad (Chapter III). The increase in the heparin-
releasable LPL pool in situ explains the observed rise in TG-
hydrolysis and the increase of the uptake of TG-FA. In controls 
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hydrolysis of chylomicron-TG correlated strongly with the hepa-
rin-releasable LPL activity in the perfusate. Such a correlation 
was not found in the hypercorticistic animals. Because there was 
not a significant correlation between hydrolysis of chylomicron-
TG and the heparin-releasable LPL-activity in the Synacthen-
treated animals, it seems that not under all conditions LPL is 
the only or major determinant of the hydrolysis of chylomicron-
TG. It is possible that Synacthen treatment induces changes in 
the enzyme configuration lowering the Km of the enzyme for chy-
lomicrons leading to a higher rate of hydrolysis with a given in 
vitro LPL activity (capacity). The increase in hydrolysis rate 
of chylomicrons in short-term treated and fasted rats leads to 
an increase in uptake of FA by the epididymal pad to levels 
found in the fed animals. Apparently hypercorticism leads in 
vivo to an increase of the FA uptake by the adipose tissue 
(Chapter IV). The discrepancy in the effects on chylomicron 
hydrolysis and FA-uptake Cthe hydrolysis is stimulated by 
Synacthen to a greater extent than the uptake) indicates a dis-
sociation between the capacity of the epididymal fat pad to 
hydrolyze and esterify FA under the influence of Synacthen. The 
percentage of the FA liberated that subsequently is taken up in 
the tissue of the fasted rats falls after Synacthen treatment to 
about the same value as in the tissue of the fed rats. 
The increased FA influx into the adipocyte from the vascu~ar 
compartment cannot alone explain the retaining of the pad weight 
during hypercorticism for prolonged periods, when during hyper-
corticism the intracellular hormone sensitive lipase activity is 
enhanced. The FA release from the adipose tissue into the vascu-
lar compartment mediated by the hormone-sensitive lipase was 
reduced in the Synacthen treated rats, both in the fasted and 
fed state. This lowering effect was more pronounced during 
stimulation of the intracellular lipolytic process with adrena-
lin. These findings are in contrast with the results of experi-
ments in isolated epididymal adipocytes from fasted rats in 
which pretreatment of the animal with cortisol or pre-incubation 
of the tissue with dexamethasone led to an enhancement of the 
adrenalin and glucagon induced lipolysis. This remarkable 
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discrepancy may be explained by the fact that in vivo or (in 
situ) the secondary hyperinsulinism in hypercorticistic rats 
counteracts the increased intracellular lipolysis. 
Furthermore corticosteroids stimulate the reesterification rate 
of fatty acids in the adipocyte. This results in a netto influx 
<decreased efflux) of fatty acids in (from) the epididymal fat 
pad leading to a balanced state in which the fat pad can retain 
its weight during hypercorticism. 
Synacthen treatment in fed rats leads to a marked increase in 
LPL activity in acetone-ether powders of the adipose tissue, a 
slight increase in heparin-releasable LPL in situ, but not to 
changes in the heparin-elutable LPL activities in vitro. These 
data may indicate a situation in which the enzyme is confined to 
a pool not elutable by heparin in vitro and limited releasable 
in situ. 
In hypercorticistic rats a pronounced hyperinsulinemia develops 
in the fasting state. The insulin levels become comparable to 
that of the normally fed controls. Many studies have shown that 
insulin administration leads to a rise in LPL activity in adi-
pose tissue, and that the insulin effect on enzyme synthesis is 
enhanced by glucocorticoids in vitro. Possibly the synthesis 
rate of LPL in adipose tissue of hypercorticistic rats is maxi-
mal, while the transfer of LPL to the endothelial cell is impai-
red. A relative deficiency of insulin (insulin resistance) 
appeared to cause an impaired transfer of LPL to the heparin-
releasable pool as discussed above. By addition of pharmacologic 
levels of insulin (10 mU/ml) to the perfusion medium the hepa-
rin-releasable LPL activity rose from 15% to 48% of total LPL 
activity measured in the fat pad of the Synacthen treated fasted 
rats <Chapter IV). In these experiments with excess insulin 
added to the perfusion medium, insulin appeared to cause a shift 
of LPL from the intracellular to the heparin-releasable pool, 
while the total enzyme activity (the sum of the heparin-released 
LPL and the activity remaining in the perfused pad) did not 
change. Under these circumstances the stimulating effect of 
Synacthen treatment on the release of LPL was even more out-
123 
spoken than in the experiments with less (0.1 mU/ml) insulin in 
the medium. 
The results of these in situ experiments confirm the hypothesis 
that the transport of LPL from intra- to extracellular loci in 
adipose tissue is insulin-dependent. 
The anti-hypertensive treatment with beta-adrenergic receptor 
blocking agents fails to prevent the occurrence of coronary 
heart disease. The explanation may be that this treatment also 
affects lipid metabolism. The changes in plasma lipid levels may 
be such that the possible beneficial effects of the lowering of 
the blood pressure are counteracted by adverse effects on cho-
lesterol and TG. For example, in a number of studies it has been 
shown that beta-blockade can lead to an increase of plasma low-
density lipoprotein cholesterol and of plasma TG and a decrease 
of high-density lipoprotein cholesterol. Alpha-adrenergic recep-
tor blockade has an opposite effect. The effects of alpha- and 
beta-blockade have been summarized by several authors (12-15). 
Lipoprotein lipase may play an important role in the mechanism 
of action of both types of adrenergic blockers, leading to the 
changes in lipoprotein concentrations in plasma. In a clinical 
trial, that we have conducted, male patients with hypertension 
and coronary heart disease were randomly assigned to proprano-
lol or prazosin treatment to begin 6 weeks after the coronary 
artery bypass grafting (Chapter VII) . Prazosin use (mean ·2, 8 
mg/day) for three months led to a decrease in plasma TG <-35 %). 
Total cholesterol (+9%), HDL-cholesterol (+16%), especially the 
HDL-3 fraction, and LPL activity in fasting post-heparin plasma 
increased. Propranolol treatment (mean 110 mg/day) had no effect 
on the TG concentration, but plasma cholesterol (+12%) and HDL-
cholesterol (+10%), again the HDL-3 fraction, increased, as did 
the hepatic lipase activity. In the prazosin group long-term 
treatment (6-9 months) had essentially the same effect on TG and 
HDL-cholesterol, <HDL-3), while total cholesterol returned to 
basal levels. Analysis of covariance showed that prazosin treat-
ment induced a lower plasma triglyceride and a higher high-den-
sity lipoprotein cholesterol concentration, a higher high-den-
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sity lipoprotein/total cholesterol ratio and a higher lipopro-
tein lipase activity than propranolol treatment. Opposite 
effects of alpha- and beta-blockade on plasma lipids can be 
explained as resulting from inverse effects of the blockers on 
LPL activity; for prazosin possibly at the endothelial cell, 
because the adipocyte does not have alpha-1 adrenergic recep-
tors. A role for lipoprotein lipases in plasma lipid changes 
during adrenergic blockade has been suggested by Ferrara et al. 
(16). 
Post-heparin plasma LPL-activity originates from several 
tissues, especially from adipose tissue and skeletal muscles. We 
found that in the rat short-term alpha-adrenergic blockade leads 
to an increase in heart LPL activity <+14%), without an effect 
on adipose tissue LPL <Chapter VI). Beta-blockade has the oppo-
site effect <-20%). In rats fed a cholesterol-enriched diet a 
similar, but smaller effect on heart LPL was found (+5%, -12% 
respectively). In these rats a slight increase in adipose tissue 
LPL was observed (+14%), as well as for hepatic lipase (+13%), 
while treatment with propranolol had an opposite effect <-20% 
and -9% respectively). It is well known that alpha- and/or beta-
adrenergic stimuli have effects on the plasma levels of insulin 
and thyroid hormone. Insulin is an important hormone in the 
regulation of adipose tissue LPL and thyroid hormone in the 
regulation of heart-muscle LPL. In our study <Chapter VI) 
alpha-blockade tended to raise and propranolol to lower insulin 
levels. The same opposite effects were observed on tri-iodothy-
ronine levels. Inverse changes in adipose tissue and heart LPL 
are generally observed, for example during feeding and fasting. 
Under these conditions insulin seems to be the major determinant 
of the adipose tissue LPL activity. 
The experiments were all carried out in overnight fasted animals 
when insulin secretion is already depressed. It is possible that 
the effects of either drug are more pronounced in the fed 
animal. 
This thesis shows disparate effects of ACTH and corticosterone 
on adipose tissue LPL-activity in the rat, while ACTH needs 
125 
corticosterone to achieve its positive effect on LPL activity. 
In hypercorticistic rats, a block in the transport of LPL from 
the adipocyte to the endothelial site of the vascular wall 
exists which can be overcome by an excess of insulin~ 
The effects of alpha- and beta-receptor blocking agents on lipo-
protein levels in plasma could be explained by the changes in 
LPL-activity. The effects of the adrenenergic-receptor blocking 
drugs on LPL-activity are probably indirect and may be explained 
by the changes in insulin and thyroid hormone levels. 
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SUMMARY 
The enzyme lipoprotein lipase (LPL) plays an important role in 
the lipoprotein metabolism. It is the rate-limiting enzyme in 
the degradation of triglycerides (TG) from chylomicrons and 
VLDL. Therefore knowledge of the regulation of the enzyme is of 
great importance. 
In this thesis different aspects of the regulation of LPL are 
described. The regulation was investigated in vitro as well as 
in situ and in man in vivo. 
First an in situ model was established. The epididymal fat pad 
of the rat was selectively perfused. After we had made the.con-
ditions optimal, the metabolism of chylomicrons and VLDL were 
investigated in this perfused pad (Chapter II). 
We found a strong relation between the hydrolysis of chylomi-
crons and the heparin-elutable LPL pooL Furthermore, chylo.,-
micron-TG was a better substrate for LPL than VLDL-TG, at least 
in adipose tissue. 
The role of corticosteroids in the regulation of LPL was inves-
tigated by treating the animals with Synacthen (ACTH 1-24> and 
/or corticosteron. Synacthen treatment in the doses used led to 
hypercorticism, and induced an increase of the LPL activity in 
adipose tissue in fasted animals to levels found in fed controls 
<Chapter III). The increased LPL activity was found when the 
activity was measured in an extract of an acetone-ether powder 
of the epididymal fat pad. No change in LPL activity was found 
in the heparin-elutable fraction of pieces of the pad in vitro. 
In the Synacthen treated animals, the heparin~releasable LPL 
activity in the selectively perfused fat pad was higher than in 
fasted controls, but remained lower than that found in fed con-
trols. We found an increase of the hydrolysis of chylomicron-TG 
and of the uptake of the liberated fatty acids by the perfused 
fat pad, to levels found in fed controls (Chapter IV). 
By using farmacologic concentrations of insulin in the perfusion 
medium, the heparin-releasable fraction LPL increased from 15% 
to 48% of the total LPL pool in the pad. These results are an 
indication that insulin plays an important role in the transport 
of LPL from the adipocyte to the endothelial cell. 
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The fact that the Synacthen-induced increase in releasable LPL 
activity was also seen in the presence of an insulin excess 
indicates that the effect of Synacthen cannot be due to hyper-
insulinism only. 
The efflux of fatty acids from the adipose tissue, measured in 
the medium after perfusion, was less than in controls, basally 
as well as after stimulation of the intracellular lipolysis with 
adrenalin. 
The earlier observation, that the rat epididymal fat pad retain-
ed its weight during hypercorticism, while the total body weight 
is decreasing could therefore be explained by several factors. 
First: an increased influx of fatty acids, liberated by LPL from 
chylomicrons. Second: an inhibition of intracellular lipolysis 
leading to a decreased efflux of fatty acids from the adipocyte. 
In Chapter V the results are described of experiments in which 
we treated the animals with corticosterone and/or Synacthen. We 
consistently found a decreased LPL activity in adipose tissue in 
animals treated with corticosterone alone (in intact as well as 
in adrenalectomized rats). This negative effect of cortico-
sterone on LPL could be overcome by treating t~e animals 
simultaneously with Synacthen. These results indicate that ACTH 
(1-24) has a direct effect on LPL activity in the adipose tissue 
of the rat. 
The effects of alpha-1- and beta-adrenergic blockade on lipoly-
tic enzymes and plasma lipids in rats as well as in humans are 
described in the Chapters VI and VII. 
Treatment with doxazosin, a selective blocker of the alpha-1 
adrenergic receptor, leads to an increment of the LPL activity 
in the heart, while propranolol, a non-selective blocker of the 
beta-adrenergic receptor, had an opposite effect <Chapter VI). 
Using animals, who were feeded with a cholesterol-enriched diet, 
the same, albeit smaller effect was found. Liver lipase and 
adipose tissue LPL activity increased, non-significantly, in the 
doxazosin treated animals, and decreased in the propranolol 
treated group. Both forms of treatment had no effect on plasma 
TG and total cholesterol. However the cholesterol content of the 
HDL fraction rose in cholesterol-rich fed rats treated with 
131 
doxazosin. 
The effects of doxazosin and propranolol on lipolytic enzymes 
and plasma lipids can, at least partially, be ascribed to an 
increase and a decrease, respectively, of the plasma insulin 
concentration. 
In Chapter VII the results of alpha-1- and beta-blockade <prazo-
sin and propranolol respectively) on plasma lipids and lipolytic 
enzymes in humans are presented. 
Fifty-two men with mild hypertension, after coronary bypass 
grafting, were divided in two groups at random and treated for 
nine months with one of these medicaments. 
In comparison with the propranolol-treated patients plasma TG 
decreased in the prazosin treated group, while plasma total 
cholesterol and LDL cholesterol levels increased initially, but 
were back at basal levels at the end of the study. In the pro-
pranolol treated group plasma TG did ~ot change, while total 
and LDL-cholesterol increased. In both treatment groups the HDL-
cholesterol concentration rose essentially by changes in the 
HDL-3 fraction. LPL activity in post-heparin serum was higher in 
the prazosin than in the propranolol treated group. 
In conclusion: antihypertensive treatment with an alpha-1 selec-
tive adrenergic blocker gives a more favorable plasme lipid 
pattern than treatment with a non-selective beta-blocker. An 
important factor leading to this pattern is the increment in LPL 
activity. 
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SAMENVATTING 
Het enzym lipoproteine lipase (LPL> speelt een belangrijke rol 
in de vetstofwisseling. Het is het snelheidsbepalende enzym bij 
de afbraak van triglyceriden uit chylomicronen en VLDL. Inzicht 
in de regulatie van het enzym is dan ook van groat belang. 
In dit proefschrift worden verschillende aspecten van de regula-
tie van LPL beschreven. De regulatie werd zowel in vitro als in 
situ (en bij de mens in vivo) onderzocht. 
Eerst werd een in situ model opgesteld. Het epididymale vet-
kwabje van de rat werd selectief geperfundeerd. Nadat de condi-
ties optimaal waren gemaakt werd het metabolisme van chylomicro-
nen en VLDL onderzocht in dit geperfundeerde vetkwabje (hoofd-
stuk II). 
Hierbij bleek dat de hydrolyse van triglyceriden in chylomicro-
nen sterk gecorreleerd is met de door heparine te elueren pool 
LPL. Tevens kwam naar voren dat chylomicron-TG een beter sub-
straat is voor vetweefsel LPL dan VLDL-TG. 
De rol van corticosteroiden in de regulat~e van LPL werd nage-
gaan door proefdieren te behandelen met Synacthen ACTH 1-24> 
en/of corticosteron. Het bleek dat hypercorticisme op basis van 
Synacthen de LPL activiteit verhoogt in vetweefsel van gevaste 
dieren tot een niveau gevonden in gevoede controle dieren 
(hoofdstuk III). De verhoging van LPL activiteit werd gevo~den 
als we de activiteit maten in een aceton-ether poeder van het 
totale vetkwabje en niet in de met heparine te elueren LPL-frac-
tie uit stukjes vetweefsel in vitro. Hoewel bij selectieve per-
fusie van het epididymale vetkwabje, van het met Synacthen voor-
behandelde dier, bleek dat de in situ met heparine te elueren 
LPL pool wel steeg, maar niet tot het niveau van het gevoede 
dier. Er werd wel een stijging waargenomen van de hydrolyse van 
TG en opname van de hierbij vrijgekomen vetzuren door het geper-
fundeerde kwabje in gevaste, behandelde dieren, tot het niveau 
gevonden in gevoede ratten (hoofdstuk IV). 
Door gebruik te maken van farmacologische concentraties insuline 
in het perfusie medium, steeg de met heparine in situ te elueren 
fractie LPL van 15% tot 48% van de totale LPL activiteit in het 
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vetkwabje. Deze bevinding duidt erop dat insuline een (belang-
rijke) rol speelt bij het transport van LPL vanuit de adipocyt 
naar de endotheelcel. Tevens dat het positieve effect van Synac-
then op de heparine-elueerbare LPL pool in situ niet alleen 
verklaard kan worden door het hyperinsulinisme op zich. Het 
vrijkomen van vetzuren uit het vetweefsel, gemeten in het perfu-
sie medium na perfusie, was minder bij met Synacthen voorbehan-
delde dieren dan bij onbehandelde, zowel basaal als na stimula-
tie van de intracellulaire lipolyse met adrenaline. 
De al eerder gedane waarneming, dat het epididymale vetkwabje 
van de rat zijn gewicht behoudt gedurende hypercorticisme,ter-
wijl het totale lichaa~sgewicht daalt, zou dus als volgt ver-
klaard kunnen worden: a. verhoogde influx van vetzuren vrijge-
maakt uit TG-rijke partikels ten gevolge van de gestegen LPL 
activiteit. b. verminderde efflux van vetzuren vanuit de adipo-
cyt ten gevolge van geremde lipolyse. 
In hoofdstuk V worden de effecten beschreven van corticosteron 
en/of Synacthen in intacte en bijnierloze proefdieren op LPL 
activiteit i~ vetweefsel. Een consistente bevinding was dat 
hypercorticis~e op basis van corticosteron leidt tot een verla-
ging van de LPL activiteit bij intacte zowel als bij geadrena-
lectomeerde ratten. Deze verlaging kan teniet gedaan worden door 
het dier tegelijkertijd te behandelen met Synacthen. Deze resul-
taten wijzen erop dat ACTH (1-24) een direct effect heeft op de 
LPL activiteit in vetweefsel van de rat. In bovengenoemde expe-
rimenten viel tevens op dat de hypercorticistische dieren met 
vergelijkbare corticosteron concentraties in het bleed (na Sy-
nacthen dan wel corticosteron behandeling), ook vergelijkbare 
insuline concentraties hadden. Gelet op de tegengestelde effec-
ten van beide behandelingen op de LPL activiteit, is ook dit een 
aanwijzing dat het effect van ACTH (1-24) op LPL niet alleen 
verklaard kan worden door het optredende hyperinsulinisme. 
De hoofdstukken VI en VII beschrijven de effecten van alpha- en 
beta-adrenerge receptor blokkade op lipolytische enzymen en 
plasma lipiden bij de rat en bij de mens. 
In de rat leidt doxazosin, een medicament dat de alpha-1 adre-
nerge receptoren blokkeert, tot een stijging van de LPL activi-
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teit in het hart, terwijl propranolol, dat ~iet-selectief de 
beta-adrenerge receptor blokkeert, een tegengesteld effect heeft 
<hoofdstuk VI). Werden de dieren gevoed met een met cholesterol-
verrijkt dieet dan werd een zelfde, doch kleiner effect gevonden 
op de LPL activiteit in het hart. De activiteiten van leverlipa-
se en vetweefsel LPL stegen niet significant in de met doxazosin 
behandelde dieren en daalden in de met propranolol behandelde 
groep. 
Beide behandelingen hadden geen effect op plasma TG of het to-
taal cholesterol. Het cholesterolgehalte in de HDL-fractie steeg 
in de met doxazosin behandelde dieren. De gevonden effecten van 
doxazosin en propranolol op vetweefsel LPL en plasma lipiden 
kunnen, tenminste deels, toegeschreven worden aan verhoging 
respectivelijk verlaging van de insuline concentratie in het 
plasma. 
Hoofdstuk VII geeft de resultaten van alpha-1- en beta-blokkade 
(respectievelijk prazo::;in en propranolol) op plasma lipiden en 
lipolytische enzymen bij de mens. Tweeenvijftig mannen met milde 
hypertensie, werden na een kransslagaderoperatie, "at random" 
behandeld met een van beide medicamenten gedurende negen maan-
den. 
In vergelijking met propranolol behandelde patienten daalt de 
plasma TG-concentratie in de met prazosin behandelde groep, 
terwijl he't plasma totaal cholesterol en LDL-cholesterol aanvan-
kelijk stegen. De laatste twee grootheden waren echter aan het 
eind van het onderzoek terug op het uitgangsniveau. In de met 
propranolol behandelde mensen bleef het plasma-TG constant, en 
stegen zowel het totale als het LDL-cholesterol blijvend. In 
beide behandelingsgroepen steeg het HDL-cholesterol, voorname-
lijk ten gevolge van toename van de HDL-3 fractie. 
De LPL activiteit in post-heparine serum was in de met prazosin 
behandelde groep hager dan in de met propranolol behandelde. 
Concluderend leidt anti-hypertensieve therapie met een selec-
tieve alpha-1 adrenerge blokker als prazosin tot een gunstiger 
plasma lipiden patroon dan tijdens behandeling met propranolol. 
Een belangrijke factor bij de tot standkoming van dit patroon is 
de verhoogde LPL activiteit. 
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